28.9.2006

Official Journal of the European Union

C 233/5

STATE AID — ITALY

State aid No C 31/2006 (ex N 612/2005) — Urgent measures to prevent bird flu

Invitation to submit comments pursuant to Article 88(2) of the EC Treaty

(2006/C 233/05)

By means of the letter dated of 4 July 2006, reproduced in the authentic language on the pages following this summary, the Commission notified Italy of its decision to initiate the procedure laid down in Article 88(2) of the EC Treaty concerning the abovementioned aid.

Interested parties may submit their comments on the aid in respect of which the Commission is initiating the procedure within one month of the date of publication of this summary and the following letter, to:

European Commission

Directorate-General for Agriculture and Rural Development

Directorate H2

Office: Loi 130 5/128

B-1049 Brussels

Fax: (32-2) 296 76 72

These comments will be communicated to Italy. Confidential treatment of the identity of the interested party submitting the comments may be requested in writing, stating the reasons for the request.

SUMMARY

—

The Italian authorities adopted urgent measures to prevent bird flu which will be in force until 1 January 2007 under the following legislation:

a)	Article 5 of Legislative Decree No 202 of 1 October 2005 (LD 202/05) implemented by Law No 244 of 30 November 2005 (Law 244/06) (1), as amended by Article 1a(7) of Law No 81 of 11 March 2006 (Law 81/06) on the ratification of Legislative Decree No 2 of 10 January 2006.

b)	Decree of the Ministry of Agricultural Policy of 13 January 2006 (Decree of 13 January 2006) on methods for implementing the measures to withdraw from the poultry meat market in accordance with Article 5(1) and (2) of Law 244/2005 (2).

c)	Article 1a(8), (10), (11) and (12) of Law 81/06 (3).

—	Poultry farms, slaughterhouses and poultry meat processing companies, poultry meat warehouses and poultry-feed manufacturers may benefit from these measures.

—

Article 5 of LD 202/05, last amended by Article 1a(7) of Law 81/06 provides for:

a)	the purchase by AGEA of 17 000 tonnes of poultry meat and other poultry products for humanitarian aid (paragraphs 1 and 2);

b)	the suspension of tax payments, social security contributions and payments for operators in the poultry sector (paragraph 3a);

c)	granting aid for reconversion and restructuring loans for poultry businesses affected by the emergency situation in the poultry sector (paragraph 3c).

—

Article 1a, paragraphs 8, 10, 11 and 12 of Law 81/06 provides for an Emergency Poultry Fund (‘the Fund’) to be set up under the Ministry of Agricultural Policy for use in 2006:

a)	for rescue and restructuring aid for the poultry sector (in accordance with Community guidelines on state aid for rescuing and restructuring firms in difficulty);

to compensate farmers for loss of revenue or additional expenditure incurred as a result of implementing the Community, national or regional plans for preventing and eradicating bird flu and indirect damages resulting from restrictions on handling animals or production stoppages imposed by the health authorities;

c)	for aid for the cessation of production (in accordance with point 9 of the Community Guidelines on state aid for the agriculture sector — guidelines);

d)	for investments in poultry farms for biosecurity and health measures;

e)	for the slaughter of animals on the order of the health authority or for the well being of animals in the event of overpopulation of production structures or a ban on handling animals.

—

Article 1a(12) of Law 81/06 states that the implementing measures for aid funded by the Fund are to be adopted by a decree from the Ministry for Agricultural policy and the Ministry for Health. The Italian authorities undertook, in an e-mail dated 20 April 2006, to notify the above decrees to the Commission under Article 88(3) of the Treaty. The Commission notes that this Law does not constitute state aid ex se. Consequently these measures are not liable to distort competition or affect trade between Member States. The Italian authorities notified the Commission in an e-mail dated 23 May 2006 of a draft Ministerial Decree on the implementing measures for the aid financed by the Fund. As a result, this file in the dossier will examined as part of state aid No 322/2006.

—

At this stage, the Commission has doubts regarding the compatibility with the internal market of the measures provided for in Article 5 of Legislative Decree No 202/05, last amended by Article 1a(7) of Law No 81/06, as the Italian authorities have not provided any information justifying these measures in the light of the rules applicable to state aid, and in particular point 11.4 of the Community guidelines on state aid in the poultry sector (4), as well as the Community guidelines for state aid for rescuing and restructuring firms in difficulty (5).

TEXT OF THE LETTER

‘Con la presente mi pregio informarLa che la Commissione, dopo aver esaminato le informazioni trasmesse dalle autorità italiane sulla misura di cui all'oggetto, ha deciso di avviare il procedimento previsto dall'articolo 88, paragrafo 2, del trattato CE.

1. PROCEDIMENTO

1)	Con lettera del 9 dicembre 2005, protocollata il 13 dicembre 2005, la Rappresentanza permanente d'Italia presso l'Unione europea ha notificato alla Commissione le misure in oggetto a norma dell'articolo 88, paragrafo 3, del trattato.

2)	Con messaggio di posta elettronica del 2 marzo 2006, protocollato il 3 marzo 2006, le autorità italiane hanno notificato alla Commissione l'articolo 1 bis, paragrafi 8, 10, 11 e 12 del progetto di legge di conversione del decreto legge 10 gennaio 2006, n. 2 .

3)	Con fax rispettivamente del 14 febbraio 2006 (rif. AGR 4535) e del 20 marzo 2006 (rif. AGR 7800) la Commissione ha chiesto informazioni complementari.

4)	Con messaggio di posta elettronica del 20 aprile 2006, protocollato il 25 aprile 2005, le autorità italiane hanno trasmesso alcune informazioni complementari.

2. DESCRIZIONE DETTAGLIATA DELLA MISURA

Titolo

5)	Misure urgenti per la prevenzione dell'influenza aviaria

Fondamento giuridico

6)	Articolo 5 del decreto-legge 1o ottobre 2005, n. 202 (DL 202/05) convertito in legge 30 novembre 2005, n. 244 (legge 244/06) (6), modificato dall'articolo 1 bis, paragrafo 7, della legge 11 marzo 2006, n. 81 (legge 81/06) di conversione del decreto-legge 10 gennaio 2006, n. 2.

7)	Decreto del Ministero delle politiche agricole e forestali del 13 gennaio 2006 (decreto 13 gennaio 2006) recante modalità per l'applicazione delle disposizioni in materia di ritiro dal mercato di carne avicola ai sensi dell'articolo 5, commi 1 e 2, della legge 244/2005 (7).

8)	Articolo 1 bis, paragrafi 8, 10, 11 e 12 della legge 81/06 (8).

Stanziamento

Le risorse cui attingere per il finanziamento delle diverse misure provengono dal bilancio nazionale. Le autorità italiane hanno menzionato una dotazione finanziaria di 120 milioni di EUR così distribuiti: 20 milioni di EUR destinati agli aiuti alimentari e 100 milioni di EUR destinati all'istituzione del Fondo per l'emergenza avicola.

Durata

10)	Fino al 1o gennaio 2007.

Beneficiari

11)	Allevamenti avicoli, imprese di macellazione e di trasformazione di carne avicola, esercenti attività di commercio all'ingrosso di carni avicole e imprese di produzione di alimenti per il pollame.

Misure

12)

L'articolo 5 del DL 202/05, modificato dall'articolo 1 bis, paragrafo 7, della legge 81/06, prevede:

a)	l'acquisto, da parte dell'AGEA, di 17 000 tonnellate di carne di pollame e di altri prodotti avicoli da destinare agli aiuti umanitari (commi 1 e 2);

b)	la sospensione del pagamento delle imposte, dei contributi di assistenza sociale e delle rate delle operazioni creditizie e di finanziamento per gli operatori del settore avicolo (comma 3 bis);

c)	la concessione di contributi destinati a mutui per il salvataggio e la riconversione e la ristrutturazione delle imprese avicole coinvolte nella situazione di emergenza della filiera avicola (comma 3 quater).

13)

L'articolo 1 bis, commi 8, 10, 11 e 12, della legge 81/06 prevede l'istituzione presso il Ministero delle politiche agricole e forestali di un “Fondo per l'emergenza avicola” (il Fondo) con dotazione pari a 100 milioni di EUR per l'anno 2006, avente le seguenti finalità:

a)	erogazione di contributi per il salvataggio e la ristrutturazione del settore avicolo (conformemente agli Orientamenti comunitari sugli aiuti di Stato per il salvataggio e la ristrutturazione di imprese in difficoltà);

indennizzo degli allevatori per la perdita di reddito o per le spese supplementari sostenute in occasione dell'attuazione dei programmi di prevenzione ed eradicazione dell'influenza aviaria realizzati a livello comunitario, nazionale e regionale nonché per i danni indiretti provocati dalle restrizioni della movimentazione degli animali e/o dai periodi di fermo produttivo imposti dalle autorità sanitarie;

c)	erogazione di contributi a seguito della cessazione dell'attività produttiva (conformemente al punto 9 degli Orientamenti comunitari per gli aiuti di Stato nel settore agricolo);

d)	realizzazione di investimenti nelle aziende avicole per l'attuazione di misure di biosicurezza e delle misure sanitarie;

e)	macellazione degli animali imposta con provvedimento dell'autorità sanitaria per il benessere degli animali in caso di sovrappopolazione delle strutture produttive o al divieto di movimentazione del bestiame.

14)

L'articolo 1 bis, comma 12, della legge 81/06 stabilisce che le disposizione attuative degli aiuti finanziati dal Fondo saranno adottate con decreti del Ministero delle politiche agricole e forestali e del Ministero della sanità. Con messaggio di posta elettronica del 20 aprile 2006 le autorità italiane si sono impegnate a notificare alla Commissione i suddetti decreti, in applicazione dell'articolo 88, paragrafo 3, del trattato.

15)

Con e-mail del 24 maggio 2006 le autorità italiane hanno notificato alla Commissione un progetto di decreto ministeriale comportante le misure attuative degli aiuti finanziati dal Fondo. Pertanto le misure previste dall'articolo 1-bis, comma 12, della legge 81/06 saranno esaminate dalla Commissione nell'ambito del fascicolo di aiuti di Stato N 322/2006.

16)

La Commissione ha a più riprese raccomandato alle autorità italiane di non dare seguito alla misura prevista dall'articolo 5 del DL 202/05 in merito all'acquisto di carni congelate da destinare ad aiuti alimentari (9). Il decreto 13 gennaio 2006, che disciplina le modalità alle quali l'AGEA deve attenersi per l'acquisto dei prodotti avicoli di origine comunitaria, prevede i seguenti prezzi minimi d'acquisto:

Carcasse e tagli di carne	EUR/kg per le carni fresche	EUR/kg per le carni congelate
Galletti Golden e/o livornesi	2,40	2,10
Galletti “Vallespluga”	2,40	2,10
Polli	1,40	1,20
Quarti posteriori di pollo	1,40	1,20
Ali di pollo	1,00	0,80
Cosce di tacchina femmina	1,00	0,80
Cosce di tacchino maschio	1,10	0,90
Ali di tacchino maschio	1,00	0,80
Tacchino maschio (busti)	1,30	1,10
Galline faraone ed anatre	2,40	2,10

17)

Può offrire i propri prodotti ad AGEA qualsiasi persona fisica o giuridica attiva nel settore dell'allevamento e della trasformazione delle carni avicole da più di dodici mesi a decorrere dall'entrata in vigore del decreto 13 gennaio 2006 ed iscritta, per le suddette attività, nel registro delle imprese tenuto dalla Camera di commercio.

3. VALUTAZIONE DELLA MISURA

18)

In virtù dell'articolo 87, paragrafo 1, del trattato, sono incompatibili con il mercato comune, nella misura in cui incidano sugli scambi tra Stati membri, gli aiuti concessi dagli Stati, ovvero mediante risorse statali, sotto qualsiasi forma che, favorendo talune imprese o talune produzioni, falsino o minaccino di falsare la concorrenza.

19)

L'articolo 1 bis, commi 8, 10, 11 e 12 della legge 81/06 prevede l'istituzione del Fondo da utilizzare per finanziare le misure descritte al punto 13, lettere a) — e), le cui modalità di concessione saranno fissate da decreti ad hoc del Ministero delle politiche. Le autorità italiane hanno notificato alla Commissione un progetto di decreto ministeriale comportante le misure attuative degli aiuti finanziati dal Fondo. Pertanto le misure previste dall'articolo 1-bis, comma 12, della legge 81/06 saranno esaminate dalla Commissione nell'ambito del fascicolo di aiuti di Stato N 322/2006.

20)

Nella fase attuale le misure descritte ai punti 12, 16 e 17 sembrano invece corrispondere alla definizione di aiuto di Stato sopra menzionata nel senso che esse sono concesse mediante risorse statali sia sotto forma di mancato guadagno in termini di gettito fiscale per i pubblici poteri sia sotto forma di prezzi da corrispondere per l'acquisto di carni di pollame e nel senso che esse possono incidere sugli scambi a causa della posizione che l'Italia occupa nel comparto produttivo in parola (nel 2004 l'Italia era il quarto paese produttore di carni avicole nell'Unione).

21)	Tuttavia, nei casi previsti dall'articolo 87, paragrafi 2 e 3, del trattato, alcune misure possono essere considerate, in deroga, compatibili con il mercato comune.

22)

Nel caso in specie, tenuto conto delle informazioni disponibili, l'unica deroga che si potrebbe invocare è quella dell'articolo 87, paragrafo 3, lettera c), del trattato, secondo cui possono essere considerati compatibili con il mercato comune gli aiuti destinati ad agevolare lo sviluppo di talune attività o di talune regioni economiche, sempre che non alterino le condizioni degli scambi in misura contraria al comune interesse.

23)	Affinché tale deroga sia applicabile, è necessario che la Commisione non nutra alcun dubbio in merito alla problematica della compatibilità delle misure previste.

24)

Poiché attualmente le autorità italiane non hanno trasmesso nessuna informazione che giustifichi le suddette misure alla luce delle norme applicabili in materia di aiuti di Stato — segnatamente il punto 11.4 degli Orientamenti comunitari per gli aiuti di Stato nel settore agricolo (10) — e degli Orientamenti comunitari sugli aiuti di Stato per il salvataggio e la ristrutturazione di imprese in difficoltà (11), la Commissione nutre effettivamente dei dubbio per quanto riguarda la compatibilità della misura proposta con il mercato comune.

25)	La Commissione ha pertanto deciso di avviare il procedimento di indagine previsto dall'articolo 88, paragrafo 2, del trattato.

26)

Tenuto conto delle considerazioni sopra esposte, la Commissione invita le autorità italiane, nell'ambito del procedimento di cui all'articolo 88, paragrafo 2, del trattato, a presentare le proprie osservazioni ed a trasmettere qualsiasi informazione utile ai fini della valutazione della misura entro un mese a decorrere dalla data di ricezione della presente. Essa invita altresì le autorità del Suo paese a trasmettere immediatamente copia della presente ai potenziali beneficiari dell'aiuto.

27)	La Commissione rammenta alle autorità italiane l'effetto sospensivo dell'articolo 88, paragrafo 3, del trattato CE e si richiama all'articolo 14 del regolamento (CE) n. 659/1999 del Consiglio secondo cui ogni aiuto illegale può costituire oggetto di recupero presso il beneficiario.

28)

Con la presente, la Commissione avvisa le autorità italiane che informerà gli interessati tramite la pubblicazione della presente lettera e di un riepilogo della medesima nella Gazzetta ufficiale dell'Unione europea. Essa informerà altresì gli interessati nei paesi dell'EFTA che hanno firmato l'Accordo SEE tramite la pubblicazione nel supplemento SEE della Gazzetta ufficiale nonché l'Autorità di vigilanza EFTA tramite copia della presente. Tutti gli interessati sopra citati saranno invitati a presentare le proprie osservazioni entro un mese a decorrere dalla data della presente pubblicazione.’

(1) Official Gazette of the Italian Republic of 30.11.2005, general series No 279, p. 44.

(2) Official Gazette of the Italian Republic of 26.1.2006, general series No 21, p. 50.

(3) Official Gazette of the Italian Republic of 11.3.2006, ordinary supplement No 58.

(4) OJ C 28, 1.2.2000, p. 2.

(5) OJ C 244, 1.10.2004, p. 2.

(6) Gazzetta ufficiale della Repubblica italiana del 30.11.2006 — serie generale — n. 279, pag. 44.

(7) Gazzetta ufficiale della Repubblica italiana del 26.1.2006 — serie generale — n. 21, pag. 50.

(8) Gazzetta ufficiale della Repubblica italiana dell'11.3.2006; supplemento ordinario n. 58.

(9) Segnatamente con lettera D(2005)38372 del 12.12.2005 (rif. AGR 31606), con fax D(2006)9256 del 20.3.2006 (rif. AGRI 7800), entrambe della direzione generale dell'Agricoltura e dello sviluppo rurale e con lettera B4* D(2006)1927 del 12.4.2006 della direzione generale dello Sviluppo.

(10) GU C 28 dell'1.2.2000, pag. 2.

(11) GU C 244 dell'1.10.2004, pag. 2.

28.9.2006

Official Journal of the European Union

C 233/9

Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 68/2001 of 12 January 2001 on the application of Articles 87 and 88 of the EC Treaty to training aid

(2006/C 233/06)

(Text with EEA relevance)

Aid No

XT 3/06

Member State

Germany

Region

Brandenburg

Title of aid scheme or name of company receiving individual aid

INNOPUNKT 13 ‘Prospects for qualified young women in the Land of Brandenburg’

Legal basis

§§ 23, 44 Landeshaushaltsordnung des Landes Brandenburg

Annual expenditure planned or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

EUR 0,35 million

Loans guaranteed

Individual aid

Overall aid amount

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

5/2005

Duration of the scheme or individual aid award

Until 5.5.2007

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Landesagentur für Struktur und Arbeit Brandenburg GmbH

Address:

Wetzlarer Str. 54

D-14482 Potsdam

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

Aid No

XT 4/06

Member State

Germany

Region

Brandenburg

Title of aid scheme or name of company receiving individual aid

INNOPUNKT 12 ‘Future prospects due to cluster-based regional interaction processes’

Legal basis

§§ 23, 44 Landeshaushaltsordnung des Landes Brandenburg

Annual expenditure planned or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

EUR 0,8 million

Loans guaranteed

Individual aid

Overall aid amount

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

11.2004

Duration of the scheme or individual aid award

Until 30.11.2006

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Landesagentur für Struktur und Arbeit Brandenburg GmbH

Address:

Wetzlarer Str. 54

D-14482 Potsdam

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

Aid No

XT 5/06

Member State

Germany

Region

Brandenburg

Title of aid scheme or name of company receiving individual aid

INNOPUNKT 14 ‘Alliances between the cultural and business sectors promote growth and employment in Brandenburg’

Legal basis

§§ 23, 44 Landeshaushaltsordnung des Landes Brandenburg

Annual expenditure planned or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

EUR 0,58 million

Loans guaranteed

Individual aid

Overall aid amount

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

8.2005

Duration of the scheme or individual aid award

Until 30.8.2007

(The adjustment period provided for in Article 8(2) of Regulation 68/2001 is being used in order to make any adjustment needed to bring the scheme into line with the block exemption regulation then applicable. Steps are being taken to ensure that after the deadline the scheme is in keeping with the block exemption regulation or corresponding rules then in force)

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Landesagentur für Struktur und Arbeit Brandenburg GmbH

Address:

Wetzlarer Str. 54

D-14482 Potsdam

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

Aid No

XT 10/06

Member State

United Kingdom of Great Britain and Northern Ireland

Region

Scotland (Local Authorities)

Title of aid scheme or name of company receiving individual aid

Support for SMEs for training

Legal basis

Section 20 of Local Government in Scotland Act 2003

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

GBP 2 million

Loans guaranteed

Individual aid

Overall aid amount

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

From 1.1.2006

Duration of scheme or individual aid award

Until 31.12.2006

Objective of aid

General training

Yes

Specific training

Yes

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Scottish Executive

Address:

State Aid Unit

Meridian Court

5 Cadogan Street

Glasgow G2 6AT

United Kingdom

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

Aid No

XT 11/06

Member State

United Kingdom

Region

West Wales & The Valleys Objective 1 Region

Title of aid scheme or name of company receiving individual aid

Energy Tech Limited

Legal basis

Council Regulation (EC) No. 1260/99

The Structural Funds (National Assembly for Wales) Regulations 2000 (no./906/2000)

The Structural Funds (National Assembly for Wales) Designation2000

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

Loans guaranteed

Individual aid

Overall aid amount

GBP 19 600

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

From 17.1.2006

Duration of scheme or individual aid award

Until 31.12.2006

NB. As noted above, the grant was committed prior to 31 December 2006. Payments against this commitment will, potentially (in line with N+2) continue until 30 April 2008

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

Limited to specific sectors

Yes

Other services (Renewable Energy)

Yes

Name and address of the granting authority

Name:

National Assembly for Wales

Address:

C/o Welsh European Funding Office

Cwm Cynon Business Park

Mountain Ash CF45 4ER

United Kingdom

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

Aid No

XT 12/06

Member State

United Kingdom

Region

London

Title of aid scheme or name of company receiving individual aid

Kessler Limited (Lean Learning Academy)

Legal basis

Section 4 RDA Act 1998

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

Loans guaranteed

Individual aid

Overall aid amount

GBP 123 000

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

From 21.3.2006

Duration of scheme or individual aid award

Until 17.7.2006

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

London Development Agency

Address:

Devon House, 58

60 St Katherines Way

London. E1W 15X

United Kingdom

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

Aid No

XT 14/06

Member State

Deutschland

Region

Brandenburg

Title of aid scheme or name of company receiving individual aid

IHK Projektgesellschaft mbH

Legal basis

§§ 23, 44 Landeshaushaltsordnung des Landes Brandenburg

Annual expenditure planned or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

Loans guaranteed

Individual aid

Overall aid amount

EUR 0,28 million

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

23.2.2006

Duration of the scheme or individual aid award

Until 15.12.2007

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Landesagentur für Struktur und Arbeit Brandenburg GmbH

Address:

Wetzlarer Str. 54

D-14482 Potsdam

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

Aid No

XT 19/06

Member State

United Kingdom

Region

London

Title of aid scheme or name of company receiving individual aid

Richard Edward Limited (Lean Learning Academy)

Legal basis

Section 4 RDA Act 1998

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

Loans guaranteed

Individual aid

Overall aid amount

GBP 72 700

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

From 21.3.2006

Duration of scheme or individual aid award

Until 17.7.2006

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

London Development Agency

Address:

Devon House, 58

60 St Katherines Way

London. E1W 15X

United Kingdom

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

Aid No

XT 22/06

Member State

United Kingdom

Region

West Midlands

Title of aid scheme or name of company receiving individual aid

Accelerate — Training Support for the West Midlands Automotive Cluster

Legal basis

Employment Act 1973 — Section 2(1) and 2(2) as substantiated by Section 25 of the Employment and Training Action1998 and the Industrial Development Act 1982, Section 7 & 11

Regional Development Agencies Act 1998 — Section 5 & 6

Greater London Authority Action 1999

Leasehold and Reform, Housing and Urban Act 1993

National Lottery Act, 1998

Local Government Act, 2000 — Section 2

Housing Grant Construction and Regeneration Act 1996 — Section 126

Employment and Training Act 1993 — Section 2

Leasehold, Housing and Urban Development Act 1993 — Part 3

Learning and Skills Council Act 2000

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

GBP 25 million

Loans guaranteed

Individual aid

Overall aid amount

GBP 150 000

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

From 1.1.2006

Duration of scheme or individual aid award

Until 31.12.2006

Objective of aid

General training

Yes

Specific training

Yes

Economic sectors concerned

All sectors eligible for training aid

Limited to specific sectors

Yes

—	All manufacturing

Yes

Name and address of the granting authority

Name:

Birmingham Chamber of Commerce and Industry

Address:

75 Harborne Road, Edgbaston

Birmingham, B15 3DH

United Kingdom

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

Aid No

XT 24/06

Member State

Belgium

Region

Vlaanderen

Title of aid scheme or name of company receiving individual aid

Van Hool

Bernard van Hoolstraat 58

B-2500 Lier

Legal basis

Decreet van 31 januari 2003

Annual expenditure planned or overall amount of aid granted to the company

Aid scheme

Annual overall amount

Loans guaranteed

Individual aid

Overall aid amount

EUR 953 063

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

12.5.2006

Duration of scheme or individual aid award

Until 30.7.2008

Objective of aid

General training

Yes

Specific training

Yes

Economic sectors concerned

Limited to specific sectors

Yes

Motor vehicles

Yes

Name and address of the granting authority

Name:

Vlaamse Gewest

Address:

Markiesstraat 1

B-1000 Brussel

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

Aid No

XT 25/06

Member State

Belgium

Region

Vlaanderen

Title of aid scheme or name of company receiving individual aid

P&O Ports Antwerp

Nieuwe Westweg — Haven 742

B-2040 Antwerpen

Legal basis

Decreet van 31 januari 2003

Annual expenditure planned or overall amount of aid granted to the company

Aid scheme

Annual overall amount

Loans guaranteed

Individual aid

Overall aid amount

EUR 999 261

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

19.5.2006

Duration of scheme or individual aid award

Until 30.8.2008

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

Limited to specific sectors

Yes

Maritime transport services

Yes

Name and address of the granting authority

Name:

Vlaamse Gewest

Address:

Markiesstraat 1

B-1000 Brussel

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

28.9.2006

Official Journal of the European Union

C 233/17

(2006/C 233/07)

(Text with EEA relevance)

Aid No	XT 16/06
Member State	Hungary
Region	Entire country
Title of aid scheme or name of company receiving an individual aid	Training aid from the regional development appropriation
Legal basis	A területfejlesztési célelőirányzat felhasználásának részletes szabályairól szóló, a 17/2006. (I. 26.) Korm. rendelettel módosított 26/2003. (III. 4.) Korm. rendelet 24/A. §
Annual expenditure planned or overall amount of individual aid granted to the company	Aid scheme	Annual overall amount (2006)	EUR 3 958 300
		Annual overall amount (2007)	EUR 1 227 985
		Loans guaranteed
	Individual aid	Overall aid amount
		Loans guaranteed
Maximum aid intensity	In conformity with Article 4(2)-(6) of the Regulation		Yes
Date of implementation	29.1.2006
Duration of the scheme or individual aid award	30.6.2007
Objective of aid	General training		Yes
	Specific training		Yes
Economic sectors concerned	All sectors eligible for training aid		Yes
Name and address of the granting authority	Name: Országos Területfejlesztési Hivatal, Regionális Fejlesztés Operatív Program és INTERREG Közösségi Kezdeményezés Irányító Hatósága
	Address: H-Budapest — 1015. Hattyú u. 14. Contact person: Szigeti Ferenc Albert
Large individual aid grants	In conformity with Article 5 of the Regulation		Yes

Aid No	XT 21/06
Member State	Republic of Hungary
Region	Entire country
Title of aid scheme or name of company receiving an individual aid	EQUAL Community Initiative
Legal basis	Az EQUAL Közösségi Kezdeményezés fejezeti kezelésű előirányzat felhasználásával kapcsolatos szabályokról szóló 33/2004. (XII. 23.) FMM rendelet
Annual expenditure planned or overall amount of individual aid granted to the company	For 2005: EUR 13 649 200 (1)
Maximum aid intensity	For general education gross aid intensity cannot exceed 60% for large companies and 80% for micro-, small- and medium-sized enterprises. For special education gross aid intensity cannot exceed 35% for large companies and 45% for micro-, small- and medium-sized enterprises. For both general and special education aid intensity can be increased by a further 10% if it is for the education of a disadvantaged person
Date of implementation	Start of the aid programme: 1.1.2005
Duration of the scheme or individual aid award	31.12.2006
Objective of aid	The aim of the EQUAL Community Initiative is to develop innovative methods to tackle discrimination and inequalities on the labour market via the Development Partnership and with the help of economic operators, including undertakings. EQUAL helps to implement the European Employment Strategy
Economic sectors concerned	All sectors
Name and address of the granting authority	Name: Foglalkoztatáspolitikai és Munkaügyi Minisztérium Humánerőforrás-fejlesztési Operatív Program és EQUAL Program Irányító Hatóság
Name and address of the granting authority	Address: H-1054 Budapest, Alkotmány u. 3.

Aid No

XT 23/06

Member State:

Italy

Region

Molise, with differing aid intensities according to the area where the measure is implemented

Title of aid scheme or name of company receiving individual aid Regional Economic Development Plan:

Multiannual programme of measures designed to promote economic recovery in Molise following disasters — Open notice concerning the granting of aid to give integrated support to firms

Legal basis

Ordinanza del Presidente del Consiglio dei Ministri n. 3268 del 12 marzo 2003, e successive, che ha nominato il Presidente della Regione Molise Commissario Delegato per gli eccezionali eventi sismici del 31 ottobre 2002 e per quelli meteorologici del gennaio 2003 ed ha previsto, all'art. 15, la predisposizione di un Programma pluriennale d'interventi diretti a favorire la ripresa produttiva nel territorio della Regione Molise.

Tale Programma è stato approvato dalla Giunta regionale del Molise con Deliberazione n. 841 del 9 giugno 2004 e dal Comitato Interministeriale per la Programmazione Economica con Deliberazione n. 32 del 29 settembre 2004 (pubblicata nella Gazzetta Ufficiale della Repubblica Italiana n. 289 del 10 dicembre 2004).

For the legal basis, see the specific section on the multiannual economic regeneration programme for Molise, on the region's official website (www.regione.molise.it)

Annual expenditure planned or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

Average over three years

EUR 0,53 million

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation:

16.2.2006

Duration of scheme or individual aid award

Until 30.6.2008

Objective of aid

General training

Yes

Specific training

Yes

Economic sectors concerned

Limited to specific sectors

Yes

Other manufacturing

Yes

Other services

Yes

Name and address of the granting authority

Name:

Commissario Delegato per l'Attuazione Operativa del Programma ex art. 15

Address:

via XXIV Maggio, 130

I-86100 Campobasso

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

Aid No

XT 56/04

Member State

United Kingdom

Region

Northern Ireland

Title of aid scheme or name of company receiving individual aid

Company Development Programme

Legal basis

The Industrial Development (NI) Order 1982

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

GBP 7,5 million

Loans guaranteed

Individual aid

Overall aid amount

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

From 2.2.2001

Duration of scheme or individual aid award

Until 31.12.2006

Objective of aid

General training

Yes

Specific training

Yes

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Invest NI

Address:

44-58 May Street

Belfast BT1 4NN

United Kingdom

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

(1) Data contains the total annual budget for the EQUAL programme for 2005. The budget also contains measures not constituting State aid. (Calculated with exchange rate HUF 250 = EUR 1.)

28.9.2006

Official Journal of the European Union

C 233/21

List of marketing authorisations granted by the EEA EFTA States for the first half of 2003

(2006/C 233/08)

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note, at the meeting on 10 March 2006, the following lists concerning marketing authorisations for medicinal products for the period 1 January — 30 June 2003:

Annex I

List of new marketing authorisations

Annex II

List of renewed marketing authorisations

Annex III

List of extended marketing authorisations

Annex IV

List of withdrawn marketing authorisations

ANNEX I

1. New Marketing Authorisations:

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January — 30 June 2003:

EU-Number	Product	Country	Date of authorisation
EU/1/00/131/031-050	PegIntron	Liechtenstein	31.1.2003
EU/1/00/134/013-021	Lantus	Liechtenstein	31.5.2003
EU/1/00/146/027	Keppra	Liechtenstein	31.3.2003
EU/1/00/147/001/NO-008/NO	Hexavac	Norway	30.1.2003
EU/1/01/171/009-010	Rapamune	Liechtenstein	31.1.2003
EU/1/01/176/004-006	Zometa	Liechtenstein	31.5.2003
EU/1/01/179/001/NO	Osteogent Protein 1	Norway	24.4.2003
EU/1/01/183/001/NO-017/NO	HBVAXPRO	Norway	5.3.2003
EU/1/01/188/004-006	Fabrazyme	Liechtenstein	31.1.2003
EU/1/01/195/008-015	Liprolog	Liechtenstein	31.3.2003
EU/1/02/201/005-006	Protopic	Liechtenstein	31.5.2003
EU/1/02/202/005-006	Protopy	Liechtenstein	31.5.2003
EU/1/02/216/002	Invanz	Liechtenstein	31.5.2003
EU/1/02/224/001/NO-005/NO	Ambirix	Norway	8.1.2003
EU/1/02/226/001/IS	InductOs	Iceland	19.3.2003
EU/1/02/233/001-015	Insulatard	Liechtenstein	31.1.2003
EU/1/02/238/001	Zavesca	Liechtenstein	31.1.2003
EU/1/02/239/001/NO-024/NO	Bextra	Norway	9.4.2003
EU/1/02/239/001-010/IS	Bextra tablets 10 mg*	Iceland	22.5.2003
EU/1/02/239/001-024	Bextra	Liechtenstein	31.5.2003
EU/1/02/239/011-020/IS	Bextra tablets 20 mg*	Iceland	22.5.2003
EU/1/02/239/021-024/IS	Bextra tablets 40 mg*	Iceland	22.5.2003
EU/1/02/240/001-003	Somavert	Liechtenstein	31.1.2003
EU/1/02/242/001/NO-024/NO	Valdyn	Norway	9.4.2003
EU/1/02/242/001-024	Valdyn	Liechtenstein	31.5.2003
EU/1/02/244/001/NO-024/NO	Kudeq	Norway	9.4.2003
EU/1/02/244/001-024	Kudeq	Liechtenstein	31.5.2003
EU/1/02/245/001	Theryttrex	Liechtenstein	31.1.2003
EU/1/02/245/001-002/IS	Theryttrex radioact. precursor	Iceland	7.2.2002
EU/1/02/246/001/IS	Carbaglu dispersible tabl.	Iceland	17.2.2003
EU/1/02/246/001/NO-002/NO	Carbaglu	Norway	6.3.2003
EU/1/03/248/001/NO-012/NO	Levitra	Norway	10.3.2003
EU/1/03/248/001-004/IS	Levitra 5 mg	Iceland	24.3.2003
EU/1/03/248/001-012	Levitra	Liechtenstein	31.3.2003
EU/1/03/248/005-008/IS	Levitra 10 mg	Iceland	24.3.2003
EU/1/03/248/009-012/IS	Levitra 20 mg	Iceland	24.3.2003
EU/1/03/249/001/NO-012/NO	Vivanza	Norway	26.5.2003
EU/1/03/249/001-004/IS	Vivanza tabl. 5 mg	Iceland	24.3.2003
EU/1/03/249/001-012	Vivanza	Liechtenstein	31.3.2003
EU/1/03/249/005-008/IS	Vivanza tabl. 10 mg	Iceland	24.3.2003
EU/1/03/249/009-012/IS	Vivanza tabl. 20 mg	Iceland	24.3.2003
EU/1/03/250/001	Ytracis	Liechtenstein	31.5.2003
EU/1/03/250/001/IS	Ytracis 1850 MBq/ml	Iceland	16.4.2003
EU/1/03/250/001/NO	Ytracis 1850 MBq/ml	Norway	22.4.2003
EU/1/03/251/001	Hepsera	Liechtenstein	31.3.2003
EU/1/03/251/001/IS	Hepsera tabl. 10 mg	Iceland	4.4.2003
EU/1/03/251/001/NO	Hepsera	Norway	26.3.2003
EU/1/03/252/001/NO-003/NO	Fuzeon	Norway	5.6.2003
EU/1/03/252/001-002/IS	Fuzeon powder and solv. for sol. for inj.	Iceland	20.6.2003
EU/1/03/252/003/IS	Fuzeon powder for sol. for inj.	Iceland	20.6.2003
EU/1/96/007/021-028	Humalog	Liechtenstein	31.1.2003
EU/1/96/011/001-004	Caelyx	Liechtenstein	31.3.2003
EU/1/97/054/001 and 003-005	Viracept	Liechtenstein	31.3.2003
EU/1/98/069/004a, 4b	Plavix	Liechtenstein	31.3.2003
EU/1/98/070/004a, 4b	Iscover	Liechtenstein	31.3.2003
EU/1/98/084/002	Simulect	Liechtenstein	31.3.2003
EU/1/99/103/004	ReFacto	Liechtenstein	31.1.2003
EU/2/00/021/001/NO-002/NO	Rabigen	Norway	19.5.2003
EU/2/00/022/001/NO-004/NO	Ibaflin	Norway	19.5.2003
EU/2/00/022/001a, b, 002a, b	Ibaflin	Liechtenstein	31.3.2003
EU/2/00/022/003a, b, 004a, b	Ibaflin	Liechtenstein	31.3.2003
EU/2/00/022/005-012	Ibaflin	Liechtenstein	31.3.2003
EU/2/00/024/001/NO	Pruban	Norway	6.5.2003
EU/2.2.20033/001/NO	Dexdomitor	Norway	16.1.2003
EU/2.2.20034/001/IS	Nobivac Bb cat	Iceland	21.1.2003
EU/2.2.20035/001-006	SevoFlo	Liechtenstein	31.1.2003
EU/2.2.20036/001-002	Nobilis OR inac	Liechtenstein	31.1.2003
EU/2.2.20036/001-002	Nobilis OR inac	Norway	31.1.2003
EU/2.3.20037/001/NO-004/NO	ProteqFlu	Norway	24.4.2003
EU/2.3.20037/001-004	ProteqFlu	Liechtenstein	31.3.2003
EU/2.3.20038/001/NO-004/NO	ProteqFlu-Te	Norway	24.4.2003
EU/2.3.20038/001-004	ProteqFlu-Te	Liechtenstein	31.3.2003
EU/2.3.20039/001-012	Advocate	Liechtenstein	31.5.2003
EU/2.3.20039/013/NO-018/NO	Advocate	Norway	25.6.2003
EU/2/97/004/001 and 003-008	Metacam	Liechtenstein	31.3.2003
EU/2/97/005/008-009	Quadrisol	Liechtenstein	31.1.2003

ANNEX II

2. Renewed Marketing Authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January — 30 June 2003:

EU-Number	Product	Country	Date of renewal
EU/1/96/006/001/NO-003/NO	NovoSeven	Norway	14.1.2003
EU/1/96/015/001/NO-002/NO	Epivir	Norway	31.1.2003
EU/1/97/032/001/IS	LeukoScan p.f. sol. for inj.	Iceland	29.1.2003
EU/1/97/039/001/NO-004/NO	Cystagon	Norway	3.3.2003
EU/1/97/039/001-002/IS	Cystagon capsule, hard	Iceland	29.1.2003
EU/1/97/039/003-004/IS	Cystagon capsule, hard	Iceland	29.1.2003
EU/1/97/040/001-002/IS	Teslascan 0,01 mmol/ml solution for infusion	Iceland	12.5.2003
EU/1/97/045/001, 006-007/IS	Helicobacter INFAI powder for oral solution, 75 mg	Iceland	12.5.2003
EU/1/97/045/008/IS	Helicobacter INFAI powder for oral solution, 45 mg	Iceland	12.5.2003
EU/1/97/046/001-003, -010, -013/IS	Aprovel tabl. 75 mg	Iceland	18.2.2003
EU/1/97/046/004-006, -011, -014/IS	Aprovel tabl. 150 mg	Iceland	18.2.2003
EU/1/97/046/007-009, 026, 030, 033/IS	Aprovel tabl. 300 mg	Iceland	18.2.2003
EU/1/97/047/001/IS	BeneFix powd. and solv. inj. 250 IU	Iceland	15.4.2003
EU/1/97/047/001-003	BeneFix	Liechtenstein	31.3.2003
EU/1/97/047/002/IS	BeneFix powd. and solv. inj. 500 IU	Iceland	15.4.2003
EU/1/97/047/003/IS	BeneFix powd. and solv. inj. 1000 IU	Iceland	15.4.2003
EU/1/97/048/001-014	Infanrix HepB	Liechtenstein	31.1.2003
EU/1/97/048/001-014/IS	Infanrix HepB	Iceland	11.2.2003
EU/1/97/049/001-003, -010, 013/IS	Karvea tabl. 75 mg	Iceland	12.2.2003
EU/1/97/049/004-006, -012, 015/IS	Karvea tabl. 300 mg	Iceland	12.2.2003
EU/1/97/049/004-006, -011, 014/IS	Karvea tabl. 150 mg	Iceland	12.2.2003
EU/1/97/050/001/NO	Sifrol	Norway	6.1.2003
EU/1/97/050/009/NO-012/NO	Sifrol	Norway	6.1.2003
EU/1/97/051/001-002/IS	Mirapexin tab. 0,088 mg	Iceland	31.1.2003
EU/1/97/051/003-004/IS	Mirapexin tab. 0,18 mg	Iceland	31.1.2003
EU/1/97/051/005-006/IS	Mirapexin tab. 0,035 mg	Iceland	31.1.2003
EU/1/97/051/007-008/IS	Mirapexin tab. 0,7 mg	Iceland	31.1.2003
EU/1/97/051/009-010/IS	Mirapexin tab. 1,1 mg	Iceland	31.1.2003
EU/1/97/052/001/NO-006/NO	Daquiran	Norway	28.1.2003
EU/1/97/052/009/NO-010/NO	Daquiran	Norway	28.1.2003
EU/1/97/053/001/NO-005/NO	Cerezyme	Norway	6.1.2003
EU/1/97/053/001-002/IS	Cerezyme 200U	Iceland	10.2.2003
EU/1/97/053/001-005	Cerezyme	Liechtenstein	31.1.2003
EU/1/97/053/003-005/IS	Cerezyme 400U	Iceland	10.2.2003
EU/1/97/054/001/IS	Viracept 50 mg/g oral powder	Iceland	13.5.2003
EU/1/97/054/001/NO	Viracept	Norway	18.2.2003
EU/1/97/054/003/IS	Viracept tablets 250 mg	Iceland	13.5.2003
EU/1/97/054/003/NO-005/NO	Viracept	Norway	18.2.2003
EU/1/97/054/005/IS	Viracept film coated tablets 250 mg	Iceland	13.5.2003
EU/1/97/055/001/IS	Viramune tabl. 200 mg	Iceland	10.4.2003
EU/1/97/055/001/NO-002/NO	Viramune	Norway	6.3.2003
EU/1/97/055/001-002	Viramune	Liechtenstein	31.3.2003
EU/1/97/055/002/IS	Viramune mixt. susp. 50 mg/5ml	Iceland	10.4.2003
EU/1/97/057/001	Quadramet	Liechtenstein	31.3.2003
EU/1/97/057/001/IS	Quadramet solution for injection 1,3 GB/ml	Iceland	16.5.2003
EU/1/97/057/001/NO	Quadramet	Norway	5.5.2003
EU/1/98/065/001/NO-002/NO	Optison	Norway	20.6.2003
EU/1/98/065/001-002	Optison	Liechtenstein	31.5.2003
EU/1/98/065/001-002/IS	Optison, solution for injection	Iceland	25.6.2003
EU/2/98/007/001-003	Clomicalm	Liechtenstein	31.5.2003
EU/2/98/008/001/NO-004/NO	Neocolipor	Norway	18.6.2003
EU/2/98/008/001-004	Neocolipor	Liechtenstein	31.5.2003

ANNEX III

3. Extended Marketing Authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January — 30 June 2003:

EU-Number	Product	Country	Date of extention
EU/1/00/146/027/NO	Keppra	Norway	18.3.2003
EU/1/01/171/009-010/IS	Rapamune filmc. tablets 2 mg	Iceland	11.6.2003
EU/1/01/171/009-010/NO	Rapamune	Norway	29.1.2003
EU/1/01/176/004/NO-006/NO	Zometa	Norway	29.4.2003
EU/1/01/176/004-006/IS	Zometa, concentrate for sol. for infus	Iceland	22.3.2003
EU/1/96/015/003/NO	Epivir	Norway	4.2.2003
EU/1/98/084/002/NO	Simulect	Norway	18.3.2003
EU/1/99/103/004/NO	ReFacto	Norway	13.3.2003
EU/1/99/127/040/NO-044/NO	Introna	Norway	21.1.2003
EU/2/00/022/009/NO-12/NO	Ibaflin	Norway	18.6.2003

ANNEX IV

4. Withdrawn Marketing Authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January — 30 June 2003:

EU-Number	Product	Country	Date of withdrawal
EU/1/00/142/003/IS	Novomix 30 Penfill	Iceland	1.1.2003
EU/1/00/142/003/NO	Novomix 30 Penfil	Norway	12.3.2003
EU/1/00/142/006/IS	Novomix 30 Novolet	Iceland	1.1.2003
EU/1/00/142/006/NO	Novomix 30 Novolet	Norway	12.3.2003
EU/1/96/021/001/NO-010/NO	Olansek	Norway	27.5.2003
EU/1/96/021/001-010	Olansek	Liechtenstein	31.3.2003
EU/2/00/019/004	Eurifel FelV	Liechtenstein	31.5.2003
EU/2/00/019/004/NO	Eurifel FelV	Norway	27.5.2003

28.9.2006

Official Journal of the European Union

C 233/28

List of marketing authorisations granted by the EEA EFTA States for the second half of 2003

(2006/C 233/09)

Annex I

List of new marketing authorisations

Annex II

List of renewed marketing authorisations

Annex III

List of extended marketing authorisations

Annex IV

List of withdrawn marketing authorisations

ANNEX I

1. New Marketing Authorisations:

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July — 31 December 2003:

EU-Number	Product	Country	Date of authorisation
EU/1/00/141/001/IS	Myocet conc. F. inf. Liposomes	Iceland	31.7.2003
EU/1/00/150/011-015	Actos	Liechtenstein	30.9.2003
EU/1/00/151/009-013	Glustin	Liechtenstein	30.9.2003
EU/1/00/165/007	Ovitrelle	Liechtenstein	30.11.2003
EU/1/02/206/005-008	Arixtra	Liechtenstein	30.11.2003
EU/1/02/207/005-008	Quixidar	Liechtenstein	30.11.2003
EU/1/02/219/010-013	Ebixa	Liechtenstein	30.9.2003
EU/1/02/229/036-037	Actraphane	Liechtenstein	30.9.2003
EU/1/02/230/016-017	Actrapid	Liechtenstein	30.9.2003
EU/1/02/231/036-037	Mixtard	Liechtenstein	30.9.2003
EU/1/02/232/003	Velosulin	Liechtenstein	30.9.2003
EU/1/02/233/016-017	Insulatard	Liechtenstein	30.9.2003
EU/1/02/234/016-017	Protaphane	Liechtenstein	30.9.2003
EU/1/02/240/004	Somavert	Liechtenstein	30.9.2003
EU/1/02/242/001-010/IS	Valdyn tablets 10 mg	Iceland	1.7.2003
EU/1/02/242/011-020/IS	Valdyn tablets 20 mg	Iceland	1.7.2003
EU/1/02/242/021-024/IS	Valdyn tablets 40 mg	Iceland	1.7.2003
EU/1/02/244/001-010/IS	Kudeq tablets 10 mg	Iceland	1.7.2003
EU/1/02/244/011-020/IS	Kudeq tablets 20 mg	Iceland	1.7.2003
EU/1/02/244/021-024/IS	Kudeq tablets 40 mg	Iceland	1.7.2003
EU/1/03/247/001-002	Forsteo	Liechtenstein	31.7.2003
EU/1/03/247/001-002/IS	Forsteo sol for inj. in prefilled pen	Iceland	8.7.2003
EU/1/03/252/001-003	Fuzeon	Liechtenstein	31.7.2003
EU/1/03/253/001-003	Aldurazyme	Liechtenstein	31.7.2003
EU/1/03/253/001-003/IS	Aldurazyme conc. for sol. f. inf. 100 U/ml	Iceland	21.7.2003
EU/1/03/254/001	Busilvex	Liechtenstein	30.9.2003
EU/1/03/254/001/IS	Busilvex 6 mg/ml conc.f. sol. f.inf.	Iceland	22.7.2003
EU/1/03/254/001/NO	Busilvex	Norway	17.7.2003
EU/1/03/255/001/NO-003/NO	Ventavis	Norway	30.10.2003
EU/1/03/255/001-003/IS	Ventavis Nebul. sol.- Inhal. 10 microg/ml	Iceland	15.10.2003
EU/1/03/256/001/NO-006/NO	Humira	Norway	11.9.2003
EU/1/03/256/001-006	Humira	Liechtenstein	30.9.2003
EU/1/03/256/001-006/IS	Humira solution for injection	Iceland	25.9.2003
EU/1/03/257/001/NO-006/NO	Trudexa	Norway	17.9.2003
EU/1/03/257/001-006	Trudexa	Liechtenstein	30.9.2003
EU/1/03/257/001-006/IS	Trudexa solution for injection	Iceland	29.9.2003
EU/1/03/258/001/NO-006/NO	Avandamet	Norway	18.11.2003
EU/1/03/258/001-003/IS	Avandamet tabl. 1mg/500 mg	Iceland	19.11.2003
EU/1/03/258/001-006	Avandamet	Liechtenstein	30.11.2003
EU/1/03/258/004-006/IS	Avandamet tabl. 2mg/500mg	Iceland	19.11.2003
EU/1/03/259/001/NO-006/NO	Onsenal	Norway	5.11.2003
EU/1/03/259/001-004/IS	Onsenal Hard capsules 200 mg	Iceland	16.12.2003
EU/1/03/259/001-006	Onsenal	Liechtenstein	30.11.2003
EU/1/03/259/005-006/IS	Onsenal Hard capsules 400 mg	Iceland	16.12.2003
EU/1/03/260/001/NO-012/NO	Stalevo	Norway	5.11.2003
EU/1/03/260/001-004/IS	Stalevo tabl. 50/12.5/200 mg	Iceland	31.10.2003
EU/1/03/260/001-012	Stalevo	Liechtenstein	30.11.2003
EU/1/03/260/005-008/IS	Stalevo tab. 100/25/200 mg	Iceland	31.10.2003
EU/1/03/260/009-012/IS	Stalevo tabl. 150/37.5/200 mg	Iceland	31.10.2003
EU/1/03/261/001/NO-003/NO	Emtriva	Norway	5.11.2003
EU/1/03/261/001-002/IS	Emtriva hard caps. 200 mg	Iceland	8.11.2003
EU/1/03/261/001-003	Emtriva	Liechtenstein	30.11.2003
EU/1/03/261/003/IS	Emtriva oral sol. 10mg/ml	Iceland	8.11.2003
EU/1/03/262/001/NO-006/NO	Emend	Norway	15.12.2003
EU/1/03/262/001-003/IS	Emend hard caps. 80 mg	Iceland	11.12.2003
EU/1/03/262/004-006/IS	Emend hard caps. 80 mg and 125 mg (comb.)	Iceland	11.12.2003
EU/1/03/262/005/IS	Emend hard caps. 125 mg	Iceland	11.12.2003
EU/1/96/012/001-013	Bondronat	Liechtenstein	30.11.2003
EU/1/96/015/004-005	Epivir	Liechtenstein	30.9.2003
EU/1/97/033/003	Avonex	Liechtenstein	31.7.2003
EU/1/98/064/001/NO	Pylobactell	Norway	1.7.2003
EU/1/98/076/001/NO-002/NO, 004/NO-009/NO	NovoNorm	Norway	15.8.2003
EU/1/98/076/011/NO-016/NO, 018/NO-021/NO	NovoNorm	Norway	15.8.2003
EU/1/99/119/012-014	NovoRapid	Liechtenstein	31.7.2003
EU/2/00/025/001/NO-006/NO	Bayovac CSF E2	Norway	8.9.2003
EU/2/00/027/001/NO-003/NO	Pirsue	Norway	2.9.2003
EU/2/01/030/001/IS	Virbagen Omega powd. & solv. for susp. f. inj. 5 MU	Iceland	10.12.2003
EU/2/01/030/002/IS	Virbagen Omega powd. & solv. for susp. f. inj. 10 MU	Iceland	10.12.2003
EU/2/02/035/001/NO-006/NO	SevoFlo	Norway	2.9.2003
EU/2/02/035/001-006/IS	SevoFlo Inhalation vapour, liquid for dogs	Iceland	1.8.2003
EU/2/03/039/001-004 & 013-014/IS	Advocate spot on sol. for cats	Iceland	25.9.2003
EU/2/03/039/005-012 & 015-018/IS	Advocate spot on sol for dogs	Iceland	25.9.2003
EU/2/03/039/013-018	Advocate	Liechtenstein	31.7.2003
EU/2/03/040/001	Gonazon	Liechtenstein	30.9.2003
EU/2/03/040/001/IS	Gonazon solution injection 1.600 microg/ml	Iceland	30.10.2003
EU/2/03/040/001/NO	Gonazon	Norway	18.8.2003
EU/2/03/041/001/NO-005/NO	Draxxin	Norway	10.12.2003
EU/2/03/041/001-005	Draxxin	Liechtenstein	30.11.2003
EU/2/03/041/001-005/IS	Draxxin sol for injection, cattle and pigs	Iceland	12.12.2003
EU/2/97/003/001-018	Dicural	Liechtenstein	30.9.2003
EU/2/97/004/009	Metacam	Liechtenstein	30.11.2003

ANNEX II

2. Renewed Marketing Authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July — 31 December 2003:

EU-Number	Product	Country	Date of authorisation
EU/1/00/162/001-006/IS	Prandin 0.5 mg tablets	Iceland	25.9.2003
EU/1/00/162/001-018	Prandin	Liechtenstein	30.9.2003
EU/1/00/162/001-018/NO	Prandin	Norway	15.8.2003
EU/1/00/162/007-012/IS	Prandin 1 mg tablets	Iceland	25.9.2003
EU/1/00/162/013-018/IS	Prandin 2 mg tablets	Iceland	25.9.2003
EU/1/97/047/001/NO-003/NO	Benefix	Norway	30.12.2003
EU/1/97/048/001/NO-014/NO	InfanrixHep B	Norway	20.11.2003
EU/1/97/051/001/NO-006/NO, 009/NO-012/NO	Mirapexin	Norway	1.9.2003
EU/1/98/058/001-002	Combivir	Liechtenstein	31.7.2003
EU/1/98/058/001-002/IS	Combivir 150/300 mg film coated tablets	Iceland	16.9.2003
EU/1/98/058/001-002/NO	Combivir	Norway	7.7.2003
EU/1/98/063/001-003/IS	Rebif 22 microg/0.5 ml. solution for injection	Iceland	18.9.2003
EU/1/98/063/001-006	Rebif	Liechtenstein	31.7.2003
EU/1/98/063/001-006/NO	Rebif	Norway	19.8.2003
EU/1/98/063/004-006/IS	Rebif 44 microg/0.5 ml. solution for injection	Iceland	18.9.2003
EU/1/98/064/001	Pylobactell	Liechtenstein	31.7.2003
EU/1/98/064/001/IS	Pylobactell 100 mg soluble tablet	Iceland	21.10.2003
EU/1/98/066/001-003/IS	Exelon capsules hard, 1.5 mg	Iceland	26.8.2003
EU/1/98/066/001-013	Exelon	Liechtenstein	31.7.2003
EU/1/98/066/001-013/NO	Exelon	Norway	15.7.2003
EU/1/98/066/004-006/IS	Exelon capsules hard, 3 mg	Iceland	26.8.2003
EU/1/98/066/007-009/IS	Exelon capsules hard, 4.5 mg	Iceland	26.8.2003
EU/1/98/066/010-012/IS	Exelon capsules hard, 6 mg	Iceland	26.8.2003
EU/1/98/066/013/IS	Exelon oral solution 2 mg/ml	Iceland	26.8.2003
EU/1/98/067/001/IS	MabThera Concentrate for solution for infusion 100 mg	Iceland	13.10.2003
EU/1/98/067/001-002	Mabthera	Liechtenstein	30.9.2003
EU/1/98/067/001-002/NO	Mabthera	Norway	6.8.2003
EU/1/98/067/002/IS	MabThera Concentrate for solution for infusion 500 mg	Iceland	13.10.2003
EU/1/98/069/001-004/IS	Plavix tablets 75 mg	Iceland	20.11.2003
EU/1/98/069/001a, 1b, 2a, 2b, 3a, 3b, 4a, 4b	Plavix	Liechtenstein	30.11.2003
EU/1/98/069/001a, 1b, 2a, 2b, 3a, 3b, 4a, 4b/NO	Plavix	Norway	7.11.2003
EU/1/98/070/001-004/IS	Iscover tablets 75 mg	Iceland	20.11.2003
EU/1/98/070/001a, 1b, 2a, 2b, 3a, 3b, 4a, 4b	Iscover	Liechtenstein	30.11.2003
EU/1/98/070/001a, 1b, 2a, 2b, 3a, 3b, 4a, 4b/NO	Iscover	Norway	7.11.2003
EU/1/98/071/001-006	Xenical	Liechtenstein	30.11.2003
EU/1/98/071/001-006/IS	Xenical hard capsules 120 mg	Iceland	1.12.2003
EU/1/98/071/001-006/NO	Xenical	Norway	24.10.2003
EU/1/98/073/001-004	Evista	Liechtenstein	30.9.2003
EU/1/98/073/001-004/IS	Evista film coated tablets 60 mg	Iceland	18.9.2003
EU/1/98/073/001-004/NO	Evista	Norway	1.8.2003
EU/1/98/074/001-004	Optruma	Liechtenstein	30.9.2003
EU/1/98/074/001-004/IS	Optruma film coated tablets 60 mg	Iceland	18.9.2003
EU/1/98/074/001-004/NO	Optruma	Norway	1.8.2003
EU/1/98/075/001-002	Fortovase	Liechtenstein	30.9.2003
EU/1/98/075/001-002/IS	Fortovase soft capsule 200 mg	Iceland	19.11.2003
EU/1/98/075/001-002/NO	Fortovase	Norway	8.10.2003
EU/1/98/076/001-002, 004-007/IS	NovoNorm 0.5 mg tablets	Iceland	25.9.2003
EU/1/98/076/001-002, 004-009	NovoNorm	Liechtenstein	30.9.2003
EU/1/98/076/008-009, 011-014/IS	NovoNorm 1 mg tablets	Iceland	25.9.2003
EU/1/98/076/011-016, 018-021	NovoNorm	Liechtenstein	30.9.2003
EU/1/98/076/015-016, 018-021/IS	NovoNorm 2 mg tablets	Iceland	25.9.2003
EU/1/98/077/001-012	Viagra	Liechtenstein	30.11.2003
EU/1/98/077/001-012/NO	Viagra	Norway	11.12.2003
EU/1/98/080/001	Aldara	Liechtenstein	30.11.2003
EU/1/98/080/001/IS	Aldara cream 5%	Iceland	3.12.2003
EU/1/98/080/001/NO	Aldara	Norway	14.11.2003
EU/1/98/081/001-004	Comtan	Liechtenstein	30.11.2003
EU/1/98/081/001-004/IS	Comtan filmcoated tablets	Iceland	16.12.2003
EU/1/98/081/001-004/NO	Comtan	Norway	3.11.2003
EU/1/98/082/001-004	Comtess	Liechtenstein	30.11.2003
EU/1/98/082/001-004/IS	Comtess filmcoated tablets	Iceland	27.11.2003
EU/1/98/082/001-004/NO	Comtess	Norway	14.11.2003
EU/1/98/084/001-002	Simulect	Liechtenstein	30.11.2003
EU/1/98/084/001-002/NO	Simulect	Norway	18.11.2003
EU/1/98/085/001/NO-010/NO	Karvezide	Norway	18.12.2003
EU/1/98/086/001/NO-010/NO	CoAprovel	Norway	19.12.2003
EU/1/98/092/001-003/IS	Prometax capsules hard 1.5 mg	Iceland	29.8.2003
EU/1/98/092/001-013	Prometax	Liechtenstein	31.7.2003
EU/1/98/092/001-013/NO	Prometax	Norway	15.7.2003
EU/1/98/092/004-006/IS	Prometax capsules hard, 3 mg	Iceland	29.8.2003
EU/1/98/092/007-009/IS	Prometax capsules hard, 4.5 mg	Iceland	29.8.2003
EU/1/98/092/010-012/IS	Prometax capsules hard, 6 mg	Iceland	29.8.2003
EU/1/98/092/013/IS	Prometax oral solution 2mg/ml	Iceland	29.8.2003
EU/2/96/002/001-003/IS	Fevaxyn Pentofelsol. for inject.	Iceland	15.10.2003
EU/2/97/003/001-003/IS	Dicural 100 mg/ml oral solution	Iceland	12.10.2003
EU/2/97/003/001-018/NO	Dicural	Norway	21.8.2003
EU/2/97/003/004-015/IS	Dicural 15 mg, 50 mg, 100 mg, 150 mg film coated tablets	Iceland	12.10.2003
EU/2/97/003/016-018/IS	Dicural 50 mg/ml solution for inject.	Iceland	12.10.2003
EU/2/97/004/001/IS	Metacam 5 mg/ml solution for injection for cattle	Iceland	8.7.2003
EU/2/97/004/003-005/IS	Metacam 1.5 mg/ml oral suspension for dogs	Iceland	8.7.2003
EU/2/97/004/006/IS	Metacam 5 mg/ml solution for injection for dogs and cats	Iceland	8.7.2003
EU/2/97/004/007-008/IS	Metacam 20 mg/ml solution for injection for cattle	Iceland	8.7.2003
EU/2/97/005/001, 005/IS	Quadrisol oral gel for horses 100 mg/ml	Iceland	27.10.2003
EU/2/97/005/002-003, 006-007/IS	Quadrisol oral gel for dogs 5 mg/ml	Iceland	27.10.2003
EU/2/97/005/004/IS	Quadrisol sol. for injection	Iceland	27.10.2003
EU/2/97/005/008-009/IS	Quadrisol oral gel for dogs 1 mg/ml	Iceland	27.10.2003
EU/2/98/006/001-010	Nobilis IB 4-91	Liechtenstein	30.9.2003
EU/2/98/006/001-010/IS	Nobilis IB 4-91 sol. for injection	Iceland	21.10.2003
EU/2/98/006/001-010/NO	Nobilis IB 4-91	Norway	8.8.2003
EU/2/98/007/00/NO-003/NO	Clomicalm	Norway	1.9.2003
EU/2/98/007/001-003/IS	Clomicalm tablets 5 mg, 20 mg, 80 mg	Iceland	27.10.2003
EU/2/98/008/001-004/IS	Neocolipor suspension for injection	Iceland	22.10.2003

ANNEX III

3. Extended Marketing Authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July — 31 December 2003:

EU-Number	Product	Country	Date of extention
EU/1/00/146/027/IS	Keppra oral solution	Iceland	19.8.2003
EU/1/00/150/011/NO-015/NO	Actos	Norway	25.9.2003
EU/1/00/150/011-015/IS	Actos tablets 45 mg	Iceland	27.11.2003
EU/1/00/165/007/IS	Ovitrelle, sol. for inj. 250 microg/0.5 ml	Iceland	16.12.2003
EU/1/00/165/007/NO	Ovitrelle	Norway	7.11.2003
EU/1/02/206/005/NO-008/NO	Arixtra	Norway	21.11.2003
EU/1/02/206/005-008/IS	Arixtra solution for injection, 1.5 mg/0.3 ml.	Iceland	4.12.2003
EU/1/02/207/00/NO-008/NO	Quixidar	Norway	21.11.2003
EU/1/02/207/005-009/IS	Quixidar solution for injection, 1.5 mg/0.3 ml	Iceland	4.12.2003
EU/1/96/009/010-017/IS	Zerit caps. prolonged release	Iceland	9.10.2003
EU/1/96/012/009/NO-013/NO	Bondronat	Norway	5.11.2003
EU/1/96/015/003/NO, EU/1/96/015/004/NO-005/NO	Epivir	Norway	29.7.2003
EU/1/97/033/003/IS	Avonex sol. for injection 30 microg/0.5 ml	Iceland	7.11.2003
EU/1/97/033/003/NO	Avonex	Norway	4.7.2003
EU/2/97/004/009/IS	Metacam oral suspention for horses	Iceland	29.10.2003
EU/2/97/004/009/NO	Metacam	Norway	24.10.2003

ANNEX IV

4. Withdrawn Marketing Authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July — 31 December 2003:

EU-Number	Product	Country	Date of withdrawal
EU/1/96/021/001-010/IS	Olansek	Iceland	1.7.2003

28.9.2006

Official Journal of the European Union

C 233/37

List of marketing authorisations granted by the EEA EFTA States for the first half of 2004

(2006/C 233/10)

Annex I

List of new marketing authorisations

Annex II

List of renewed marketing authorisations

Annex III

List of extended marketing authorisations

Annex IV

List of withdrawn marketing authorisations

Annex V

List of suspended marketing authorisations

ANNEX I

1. New Marketing Authorisations:

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January — 30 June 2004:

EU-Number	Product	Country	Date of authorisation
EU/1/00/141/001/NO	Myocet	Norway	22.1.2004
EU/1/00/164/003-005	NutropinAq	Liechtenstein	31.3.2004
EU/1/02/212/026	Vfend	Liechtenstein	31.3.2004
EU/1/02/215/001-010/IS	PritorPlus tablets 40 mg and 80 mg	Iceland	10.2.2004
EU/1/03/263/001/NO-003/NO	Dukoral	Norway	11.5.2004
EU/1/03/263/001-003	Dukoral	Liechtenstein	31.5.2004
EU/1/03/264/001	Zevalin	Liechtenstein	31.1.2004
EU/1/03/264/001/IS	Zevalin 1.6 mg/ml kit for radiopharmaceut. prep.	Iceland	13.2.2004
EU/1/03/264/001/NO	Zevalin	Norway	2.2.2004
EU/1/03/265/001/NO-002/NO	Bonviva	Norway	24.3.2004
EU/1/03/265/001-002	Bonviva	Liechtenstein	31.5.2004
EU/1/03/265/001-002/IS	Bonviva filmc. tabl. 2.5 mg	Iceland	23.3.2004
EU/1/03/266/001/NO-002/NO	Ibandronic Acid Roche	Norway	24.3.2004
EU/1/03/266/001-002	Ibandronic Acid Roche	Liechtenstein	31.5.2004
EU/1/03/266/001-002/IS	Ibandronic Acid Roche film. tabl. 2.5 mg	Iceland	23.3.2004
EU/1/03/267/001/NO-007/NO	Reyataz	Norway	26.3.2004
EU/1/03/267/001-006/IS	Reyataz capsule hard 100 mg, 150 mg, 200 mg	Iceland	30.3.2004
EU/1/03/267/001-007	Reyataz	Liechtenstein	31.3.2004
EU/1/03/267/007/IS	Reyataz oral powder 50 mg/1.5 g	Iceland	30.3.2004
EU/1/03/268/001/NO-003/NO	Cholestagel	Norway	24.3.2004
EU/1/03/268/001-003	Cholestagel	Liechtenstein	31.3.2004
EU/1/03/268/001-003/IS	Cholestagel filmc. tabl. 625 mg	Iceland	5.4.2004
EU/1/03/269/001/IS	Faslodex	Iceland	7.4.2004
EU/1/03/269/001/NO	Faslodex	Norway	6.4.2004
EU/1/03/270/001/NO-002/NO	Oxybutynin Nicobrand	Norway	28.6.2004
EU/1/03/271/001/IS	Advate powder for sol. for inj. 250 IU, 500 IU, 1000 IU, 150	Iceland	1.4.2004
EU/1/03/271/001/NO-004/NO	Advate	Norway	29.3.2004
EU/1/03/271/001-004	Advate	Liechtenstein	31.5.2004
EU/1/04/272/001/NO-002/NO	Photo Barr	Norway	23.4.2004
EU/1/04/272/001-002	Photo Barr	Liechtenstein	31.5.2004
EU/1/04/272/002/IS	Photo Barr Powder for sol. for inj. 15 or 75 mg	Iceland	23.4.2004
EU/1/04/273/001	Lysodren	Liechtenstein	31.5.2004
EU/1/04/273/001/IS	Lysodren tablets 500 mg	Iceland	19.5.2004
EU/1/04/273/001/NO	Lysodren	Norway	26.5.2004
EU/1/04/274/001	Velcade	Liechtenstein	31.5.2004
EU/1/04/274/001/IS	Velcade powder for sol. for inj. 3.5 mg	Iceland	26.5.2004
EU/1/04/274/001/NO	Velcade	Norway	25.5.2004
EU/1/04/275/001/NO-002/NO	Litak	Norway	14.5.2004
EU/1/04/275/001-002	Litak	Liechtenstein	31.5.2004
EU/1/04/275/001-002/IS	Litak Solution for inj. 2 mg/ml	Iceland	14.5.2004
EU/1/04/276/001/NO-020/NO	Abilify	Norway	24.6.2004
EU/1/04/278/001/NO-009/NO	Levemir	Norway	14.6.2004
EU/1/04/278/001-009/IS	Levemir Penfill/FlexPen/InnoLet, sol f. inj.	Iceland	25.6.2004
EU/1/95/001/032	Gonal	Liechtenstein	31.1.2004
EU/1/95/001/033-035	Gonal f	Liechtenstein	31.3.2004
EU/1/97/031/045-046	NeoRecormon	Liechtenstein	31.3.2004
EU/1/97/046/016-030	Aprovel	Liechtenstein	31.5.2004
EU/1/97/049/016-030	Karvea	Liechtenstein	31.5.2004
EU/1/97/054/006	Viracept	Liechtenstein	31.5.2004
EU/1/98/066/014-018	Exelon	Liechtenstein	31.3.2004
EU/1/98/085/011-020	Karvezide	Liechtenstein	31.5.2004
EU/1/98/086/011-020	CoAprovel	Liechtenstein	31.5.2004
EU/1/98/091/001-014	Kinzalmono	Liechtenstein	31.1.2004
EU/1/98/092/014-018	Prometax	Liechtenstein	31.3.2004
EU/1/99/099/001-006	Zerene	Liechtenstein	31.5.2004
EU/1/99/113/003-004	Paxene	Liechtenstein	31.1.2004
EU/2/00/022/009-012/IS	Ibaflin oral gel 3% and 7.5%	Iceland	22.1.2004
EU/2/00/022/013-017	Ibaflin	Liechtenstein	31.3.2004
EU/2/02/032/001/IS	Gallivac HVT IDB Frosen susp. And diluent for inj.	Iceland	13.4.2004
EU/2/04/042/001/NO-004/NO	Novem	Norway	10.5.2004
EU/2/04/042/001-002/IS	Novem sol. for inj. 5 mg/ml	Iceland	31.3.2004
EU/2/04/042/001-004	Novem	Liechtenstein	31.5.2004
EU/2/04/042/003-004/IS	Novem sol. for inj. 20 mg/ml	Iceland	31.3.2004
EU/2/04/043/001/IS	Equilis StrepE lyophilisate and solvent for suspension	Iceland	11.6.2004
EU/2/97/004/010	Metacam	Liechtenstein	31.3.2004
EU/2/98/010/001-024	Econor	Liechtenstein	31.5.2004
EU/2/99/011/001	Locatim	Liechtenstein	31.5.2004
EU/2/99/014/001-011	Stronghold	Liechtenstein	31.3.2004

ANNEX II

2. Renewed Marketing Authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January — 30 June 2004:

EU-Number	Product	Country	Date of authorisation
EU/1/97/037/001/NO	Vistide	Norway	31.3.2004
EU/1/98/084/001/IS	Simulect, powder and solvent for sol. for injection, 20 mg	Iceland	27.1.2004
EU/1/98/084/002/IS	Simulect, powder and solvent for sol. for injection, 10 mg	Iceland	27.1.2004
EU/1/98/085/001-010	Karvezide	Liechtenstein	31.1.2004
EU/1/98/086/001-003,007 and 009/IS	CoAprovel, tablets, 150 mg/12,5 mg	Iceland	23.1.2004
EU/1/98/086/004-006,008 and 010/IS	CoAprovel, tablets, 300 mg/12,5 mg	Iceland	23.1.2004
EU/1/98/086/001-010	CoAprovel	Liechtenstein	31.1.2004
EU/1/98/087/001/NO-003/NO	Infergen	Norway	23.4.2004
EU/1/98/087/001-003	Infergen	Liechtenstein	31.5.2004
EU/1/98/087/001-003/IS	Infergen solution for injection, 9 micrograms	Iceland	21.6.2004
EU/1/98/089/001-016/IS	Pritor tablets, 20, 40 and 80 mg	Iceland	2.2.2004
EU/1/98/089/001-016/NO	Pritor tablets, 20, 40 and 80 mg	Norway	30.1.2004
EU/1/98/089/001-016	Pritor	Liechtenstein	31.1.2004
EU/1/98/090/001/NO-014/NO	Micardis	Norway	30.1.2004
EU/1/98/090/001-014	Micardis	Liechtenstein	31.1.2004
EU/1/98/090/001-014/IS	Micardis tablets, 20, 40 and 80 mg	Iceland	2.2.2004
EU/1/98/091/001/NO-014/NO	Kinzalmono	Norway	30.1.2004
EU/1/98/091/001-014/IS	Kinzalmono tablets, 20, 40 and 80 mg	Iceland	2.2.2004
EU/1/98/095/001/NO-002/NO	Emadine	Norway	5.4.2004
EU/1/98/095/001-004	Emadine	Liechtenstein	31.3.2004
EU/1/98/095/001-004/IS	Emadine, eye drops, solution, 0,5 mg/ml	Iceland	1.4.2004
EU/1/98/096/001-002/IS	Temodal, capsule, hard, 5 mg	Iceland	7.4.2004
EU/1/98/096/001/NO-008/NO	Temodal	Norway	6.4.2004
EU/1/98/096/001-008	Temodal	Liechtenstein	31.3.2004
EU/1/98/096/003-004/IS	Temodal, capsule, hard, 20 mg	Iceland	7.4.2004
EU/1/98/096/005-006/IS	Temodal, capsule, hard, 100 mg	Iceland	7.4.2004
EU/1/98/096/007-008/IS	Temodal, capsule, hard, 250 mg	Iceland	7.4.2004
EU/1/99/097/001/NO	Beromun	Norway	8.6.2004
EU/1/99/098/001/NO-002/NO	Zenapax	Norway	14.5.2004
EU/1/99/098/001-002	Zenapax	Liechtenstein	31.5.2004
EU/1/99/098/001-002/IS	Zenepax concentrate for solution for infusion	Iceland	23.6.2004
EU/1/99/099/001-003/IS	Zerene, capsule, hard, 5 mg	Iceland	28.4.2004
EU/1/99/099/004-006/IS	Zerene, capsule, hard, 10 mg	Iceland	28.4.2004
EU/1/99/099/001-006/NO	Zerene 5 mg, 10 mg capsules	Norway	29.4.2004
EU/1/99/101/001/NO	Regranex	Norway	30.4.2004
EU/1/99/101/001	Regranex	Liechtenstein	31.5.2004
EU/1/99/101/001/IS	Regranex, gel, 100 mcg/g	Iceland	30.4.2004
EU/1/99/102/001-003 and 007/IS	Sonata, capsule, hard, 5 mg	Iceland	29.4.2004
EU/1/99/102/001/NO-008/NO	Sonata	Norway	29.4.2004
EU/1/99/102/001-008	Sonata	Liechtenstein	31.5.2004
EU/1/99/102/004-006 and 008/IS	Sonata, capsule, hard, 10 mg	Iceland	29.4.2004
EU/1/99/110/001/NO-009/NO	Sustiva	Norway	24.5.2004
EU/1/99/110/001-009	Sustiva	Liechtenstein	31.5.2004
EU/1/99/110/001-009/IS	Sustiva filmcoated tablets, capsules and oral sol.	Iceland	28.5.2004
EU/1/99/111/001-009/IS	Stocrin tablets, capsules and oral sol.	Iceland	21.5.2004
EU/1/99/111/001/NO-009/NO	Stocrin	Norway	24.5.2004
EU/1/99/111/001-009	Stocrin	Liechtenstein	31.5.2004
EU/1/99/111/002/IS	Stocrin, capsule, hard, 100 mg	Iceland	21.5.2004
EU/1/99/111/003-004/IS	Stocrin, capsule, hard, 200 mg	Iceland	21.5.2004
EU/1/99/111/005/IS	Stocrin, oral solution, 30 mg/ml	Iceland	21.5.2004
EU/1/99/111/006-007/IS	Stocrin, film-coated tablet, 300 mg	Iceland	21.5.2004
EU/1/98/085/004-006, 008, 010, 017-020/IS	Karvezide, tablets, 150 mg/12,5 mg	Iceland	22.1.2004
EU/1/98/085/001-003, 007, 009, 011-015/IS	Karvezide, tablets, 300 mg/12,5 mg	Iceland	22.1.2004
EU/2/98/009/001/NO-006/NO	Suvaxyn Aujeszky 783+ O/W	Norway	14.4.2004
EU/2/98/009/001-006	Suvaxyn Aujeszky 783+ O/W	Liechtenstein	31.3.2004
EU/2/99/011/001/IS	Locatim oral solution	Iceland	27.5.2004
EU/2/99/011/001/NO	Locatim	Norway	28.5.2004

ANNEX III

3. Extended Marketing Authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January — 30 June 2004:

EU-Number	Product	Country	Date of extention
EU/1/01/198/007/NO-010/NO	Glivec	Norway	5.1.2004
EU/1/01/198/007-010/IS	Glivec 100 mg and 400 mg filmcoated tablets	Iceland	15.1.2004
EU/1/02/212/026/IS	Vfend, powder for oral suspension 40 mg/ml	Iceland	18.6.2004
EU/1/02/212/026/NO	Vfend	Norway	5.3.2004
EU/1/95/001/033/NO-035/NO	Gonal-f	Norway	24.3.2004
EU/1/95/001/033-035/IS	GONAL-f, solution for injection in prefilled pen	Iceland	19.3.2004
EU/1/96/012/009-010/IS	Bondronat, film coated tablets 50 mg	Iceland	7.1.2004
EU/1/97/031/045/NO-046/NO	NeoRecormon	Norway	23.3.2004
EU/1/97/031/045-046/IS	NeoRecormon 30.000 IU Sol. for injection pref.syr.	Iceland	30.3.2004
EU/1/97/046/016/NO-030/NO	Aprovel	Norway	30.3.2004
EU/1/97/049/016/NO-030/NO	Karvea	Norway	30.3.2004
EU/1/97/054/006/IS	Viracept 625 mg film-coated tablets	Iceland	28.5.2004
EU/1/97/054/006/NO	Viracept	Norway	21.5.2004
EU/1/98/085/011/NO-020/NO	Karvezide	Norway	23.6.2004
EU/1/98/086/011/NO-020/NO	CoAprovel	Norway	23.6.2004
EU/2/00/022/013/NO-017/NO	Ibaflin	Norway	24.3.2004
EU/2/97/004/010/NO	Metacam	Norway	11.5.2004

ANNEX IV

4. Withdrawn Marketing Authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January — 30 June 2004:

EU-Number	Product	Country	Date of withdrawal
EU/1/00/158/001/NO-034/NO	Opulis	Norway	29.3.2004
EU/1/00/158/001-034	Opulis	Liechtenstein	31.3.2004
EU/1/00/159/001/NO-034/NO	Allex	Norway	29.3.2004
EU/1/00/159/001-034	Allex	Liechtenstein	31.3.2004
EU/1/00/159/001-034/IS	Allex	Iceland	10.3.2004
EU/1/02/208/001/NO-008/NO	Xapit	Norway	29.3.2004
EU/1/02/208/001-008	Xapit	Liechtenstein	31.3.2004
EU/1/02/242/001/NO-024/NO	Valdyn	Norway	29.3.2004
EU/1/99/106/001-003	Cotronak	Liechtenstein	31.3.2004

ANNEX V

5. Suspended Marketing Authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January — 30 June 2004:

EU-Number	Product	Country	Date of suspension
EU/1/98/093/002	Forcaltonin	Liechtenstein	31.5.2004

28.9.2006

Official Journal of the European Union

C 233/45

List of marketing authorisations granted by the EEA EFTA States for the second half of 2004

(2006/C 233/11)

Annex I

List of new marketing authorisations

Annex II

List of renewed marketing authorisations

Annex III

List of extended marketing authorisations

Annex IV

List of withdrawn marketing authorisations

ANNEX I

1. New Marketing Authorisations:

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July — 31 December 2004:

EU-Number	Product	Country	Date of authorisation
EU/1/00/134/022-029	Lantus	Liechtenstein	30.9.2004
EU/1/00/138/001/NO-012/NO	Venvia	Norway	30.7.2004
EU/1/00/139/001/NO-012/NO	Nyracta	Norway	30.7.2004
EU/1/00/143/004-006	Kogenate Bayer	Liechtenstein	30.9.2004
EU/1/01/178/001/NO	Targretin	Norway	13.7.2004
EU/1/01/184/033-044	Nespo	Liechtenstein	30.11.2004
EU/1/01/185/033-044	Aranesp	Liechtenstein	30.11.2004
EU/1/01/189/004-006	Replagal	Liechtenstein	30.9.2004
EU/1/01/191/005	Ketek	Liechtenstein	30.11.2004
EU/1/01/192/005	Levviax	Liechtenstein	30.11.2004
EU/1/01/193/002	MabCampath	Liechtenstein	30.11.2004
EU/1/02/206/009-017	Arixtra	Liechtenstein	30.11.2004
EU/1/02/207/009-017	Quixidar	Liechtenstein	30.11.2004
EU/1/02/221/009-010	Pegasys	Liechtenstein	30.11.2004
EU/1/03/258/007-012	Avandamet	Liechtenstein	30.9.2004
EU/1/03/270/001-002	Oxybutynin	Liechtenstein	31.7.2004
EU/1/03/270/001-002/IS	Oxybutynin Nicobrand transderm. patches, 3,9 mg/24hours	Iceland	28.7.2004
EU/1/04/276/001-005/IS	Abilify, tablets, 5 mg	Iceland	1.7.2004
EU/1/04/276/001-020	Abilify	Liechtenstein	31.7.2004
EU/1/04/276/006-010/IS	Abilify, tablets,10 mg	Iceland	1.7.2004
EU/1/04/276/011-015/IS	Abilify, tablets, 15 mg	Iceland	1.7.2004
EU/1/04/276/016-020/IS	Abilify, tablets, 30 mg	Iceland	1.7.2004
EU/1/04/277/001/IS	TachoSil, medicated sponge, 5,5 mg + 2,0 IU	Iceland	8.7.2004
EU/1/04/277/001/NO-004/NO	TachoSil	Norway	5.7.2004
EU/1/04/277/001-004	TachoSil	Liechtenstein	31.7.2004
EU/1/04/278/001-009	Levemir	Liechtenstein	31.7.2004
EU/1/04/279/001/NO-025/NO	Lyrica	Norway	4.8.2004
EU/1/04/279/001-005/IS	LYRICA, capsule, hard, 25 mg	Iceland	26.8.2004
EU/1/04/279/001-025	Lyrica	Liechtenstein	30.9.2004
EU/1/04/279/006-010/IS	LYRICA, capsule, hard, 50 mg	Iceland	26.8.2004
EU/1/04/279/011-013/IS	LYRICA, capsule, hard, 75 mg	Iceland	26.8.2004
EU/1/04/279/014-016/IS	LYRICA, capsule, hard, 150 mg	Iceland	26.8.2004
EU/1/04/279/017-019/IS	LYRICA, capsule, hard, 300 mg	Iceland	26.8.2004
EU/1/04/279/020-022/IS	LYRICA, capsule, hard, 100 mg	Iceland	26.8.2004
EU/1/04/279/023-025/IS	LYRICA, capsule, hard, 200 mg	Iceland	26.8.2004
EU/1/04/280/001/IS	Yentreve, gastro-resistant capsule, hard, 20 mg	Iceland	9.9.2004
EU/1/04/280/001/NO-006/NO	Yentreve	Norway	26.8.2004
EU/1/04/280/001-006	Yentreve	Liechtenstein	30.9.2004
EU/1/04/280/002-006/IS	Yentreve, gastro-resistant capsule, hard, 40 mg	Iceland	9.9.2004
EU/1/04/281/001	Erbitux	Liechtenstein	31.7.2004
EU/1/04/281/001/IS	Erbitux, solution for infusion, 2 mg/ml	Iceland	26.7.2004
EU/1/04/281/001/NO	Erbitux	Norway	9.7.2004
EU/1/04/282/001/NO-002/NO	Telzir	Norway	19.7.2004
EU/1/04/282/001-002	Telzir	Liechtenstein	30.9.2004
EU/1/04/282/001-002/IS	Telzir tablets and oral susp.	Iceland	10.8.2004
EU/1/04/283/001/IS	Ariclaim, gastro-resistant capsule, hard, 20 mg	Iceland	11.9.2004
EU/1/04/283/001/NO-006/NO	Ariclaim	Norway	27.8.2004
EU/1/04/283/001-006	Ariclaim	Liechtenstein	30.9.2004
EU/1/04/283/002-006/IS	Ariclaim, gastro-resistant capsule, hard, 40 mg	Iceland	11.9.2004
EU/1/04/284/001	Pedea	Liechtenstein	30.9.2004
EU/1/04/284/001/IS	Pedea, solution for injection, 5mg/ml	Iceland	12.8.2004
EU/1/04/284/001/NO	Pedea	Norway	18.8.2004
EU/1/04/285/001/NO-020/NO	Apidra	Norway	25.10.2004
EU/1/04/285/001-004/IS	Apidra, solution for injection,vial, 100 units/ml	Iceland	27.10.2004
EU/1/04/285/001-020	Apidra	Liechtenstein	30.11.2004
EU/1/04/285/005/012/IS	Apidra, solution for injection,cartridge, 100 units/ml	Iceland	27.10.2004
EU/1/04/285/013-020/IS	Apidra, solution for injection, pre-filled pen, 100 units/ml	Iceland	27.10.2004
EU/1/04/286/001/IS	Wilzin, capsule, hard, 25 mg	Iceland	11.11.2004
EU/1/04/286/001/NO-002/NO	Wilzin	Norway	12.11.2004
EU/1/04/286/001-002	Wilzin	Liechtenstein	30.11.2004
EU/1/04/286/002/IS	Wilzin, capsule, hard, 50 mg	Iceland	11.11.2004
EU/1/04/287/001/NO-006/NO	Osseor	Norway	18.10.2004
EU/1/04/287/001-006	Osseor	Liechtenstein	30.11.2004
EU/1/04/287/001-006/IS	Osseor, powder for oral suspension, 2g	Iceland	27.10.2004
EU/1/04/288/001/NO-006/NO	Protelos	Norway	18.10.2004
EU/1/04/288/001-006	Protelos	Liechtenstein	30.11.2004
EU/1/04/288/001-006/IS	Protelos, powder for oral suspension, 2g	Iceland	20.10.2004
EU/1/04/289/001	Angiox	Liechtenstein	30.9.2004
EU/1/04/289/001/NO	Angiox	Norway	8.10.2004
EU/1/04/290/001	Alimta	Liechtenstein	30.9.2004
EU/1/04/290/001/IS	Alimta, concentrate for solution for infusion, 500 mg	Iceland	19.10.2004
EU/1/04/290/001/NO	Alimta, concentrate for solution for infusion, 500 mg	Norway	19.10.2004
EU/1/04/291/001/NO-002/NO	Raptiva	Norway	30.9.2004
EU/1/04/291/001-001/IS	Raptiva 100 mg/ml Powder and solvent for solution for injection	Iceland	18.10.2004
EU/1/04/291/001-002	Raptiva	Liechtenstein	30.9.2004
EU/1/04/292/001/NO-012/NO	Mimpara	Norway	11.11.2004
EU/1/04/292/001-004/IS	Mimpara, film-coated tablet, 30 mg	Iceland	19.11.2004
EU/1/04/292/001-012	Mimpara	Liechtenstein	30.11.2004
EU/1/04/292/005-008/IS	Mimpara, film-coated tablet, 60 mg	Iceland	19.11.2004
EU/1/04/292/009-012/IS	Mimpara, film-coated tablet, 90 mg	Iceland	19.11.2004
EU/1/04/293/001/NO-012/NO	Parareg	Norway	11.11.2004
EU/1/04/293/001-004/IS	Parareg, film-coated tablet, 30 mg	Iceland	18.11.2004
EU/1/04/293/001-012	Parareg	Liechtenstein	30.11.2004
EU/1/04/293/005-008/IS	Parareg, film-coated tablet, 60 mg	Iceland	18.11.2004
EU/1/04/293/009-012/IS	Parareg, film-coated tablet, 90 mg	Iceland	18.11.2004
EU/1/04/294/001/NO-012/NO	Emselex	Norway	16.11.2004
EU/1/04/294/001-006/IS	Emselex 7,5 mg prolonged release tablets	Iceland	24.11.2004
EU/1/04/294/001-012	Emselex	Liechtenstein	30.11.2004
EU/1/04/294/007-012/IS	Emselex 15 mg prolonged release tablets	Iceland	24.11.2004
EU/1/04/295/001	Xagrid	Liechtenstein	30.11.2004
EU/1/04/295/001/IS	Xagrid, Capsules, hard, 0,5 mg	Iceland	29.12.2004
EU/1/04/295/001/NO	Xagrid	Norway	15.12.2004
EU/1/96/008/040-041	Puregon	Liechtenstein	30.9.2004
EU/1/96/013/001-004	Destara	Liechtenstein	31.7.2004
EU/1/96/022/019-022	Zyprexa	Liechtenstein	30.11.2004
EU/1/97/044/001-006	Tasmar	Liechtenstein	30.11.2004
EU/1/99/104/001/NO	Procomvax	Norway	17.9.2004
EU/2/04/043/001/NO	Equilis StrepE	Norway	13.9.2004
EU/2/04/044/001/IS	Aivlozin 42,5 mg/g premix for medicated feeding stuff for pigs	Iceland	22.9.2004
EU/2/04/044/001/NO	Aivlosin	Norway	8.10.2004
EU/2/04/045/001/NO-004/NO	Previcox	Norway	13.10.2004
EU/2/04/045/001-002/IS	Previcox, chewable tablet, 57 mg	Iceland	4.10.2004
EU/2/04/045/001-004	Previcox	Liechtenstein	30.9.2004
EU/2/04/045/003-004/IS	Previcox, chewable tablet, 227 mg	Iceland	4.10.2004
EU/2/04/046/001/NO-003/NO	Nobivac Piro	Norway	2.10.2004
EU/2/04/046/001-003	Nobivac Piro-606	Liechtenstein	30.9.2004
EU/2/96/001/009-010	Porcilis Porcoli	Liechtenstein	30.9.2004

ANNEX II

2. Renewed Marketing Authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July — 31 December 2004:

EU-Number	Product	Country	Date of renewal
EU/1/99/119/009/IS-011/IS	NovoRapid FlexPen, solution for injection, 100 units/ml	Iceland	11.11.2004
EU/1/99/097/001	Beromun	Liechtenstein	31.7.2004
EU/1/99/097/001/IS	Beromun, powder and solvent for solution for infusion, 1 mg	Iceland	9.8.2004
EU/1/99/100/001-002/IS	Cetrotide, powder for solution for injection, 0,25 mg	Iceland	15.9.2004
EU/1/99/100/001-003	Cetrotide	Liechtenstein	30.9.2004
EU/1/99/100/003/IS	Cetrotide, powder for solution for injection, 3 mg	Iceland	15.9.2004
EU/1/99/103/001/IS	Refacto, powder and solvent for sol. for injection, 250 a.e.	Iceland	19.8.2004
EU/1/99/103/001/NO-004/NO	ReFacto	Norway	16.8.2004
EU/1/99/103/001-004	ReFacto	Liechtenstein	30.9.2004
EU/1/99/103/002/IS	Refacto, powder and solvent for sol. for injection, 500 a.e.	Iceland	19.8.2004
EU/1/99/103/003/IS	Refacto, powder and solvent for sol. for injection, 1 000 a.e.	Iceland	19.8.2004
EU/1/99/103/004/IS	Refacto, powder and solvent for sol. for injection, 2 000 a.e.	Iceland	19.8.2004
EU/1/99/104/001	Procomvax	Liechtenstein	30.9.2004
EU/1/99/104/001/IS	Procomvax, suspension for injection	Iceland	2.9.2004
EU/1/99/107/001/IS	Rebetol, capsule, hard, 200 mg	Iceland	29.9.2004
EU/1/99/107/001/NO-003/NO	Rebetol	Norway	28.9.2004
EU/1/99/107/001-003	Rebetol	Liechtenstein	30.9.2004
EU/1/99/108/001	Ferriprox	Liechtenstein	30.9.2004
EU/1/99/108/001/IS	Ferriprox, film coated tablet, 500 mg	Iceland	22.9.2004
EU/1/99/108/001/NO	Ferriprox	Norway	27.9.2004
EU/1/99/109/001/IS	Integrilin, solution for infusion, 0,75 mg/ml	Iceland	1.10.2004
EU/1/99/109/001/NO-002/NO	Integrilin	Norway	28.9.2004
EU/1/99/109/001-002	Integrilin	Liechtenstein	30.9.2004
EU/1/99/109/002/IS	Integrilin, solution for injection, 2 mg/ml	Iceland	1.10.2004
EU/1/99/111/001-009	Stocrin	Liechtenstein	31.7.2004
EU/1/99/112/001/IS	Ziagen, film-coated tablet, 300 mg	Iceland	16.9.2004
EU/1/99/112/001/NO-002/NO	Ziagen	Norway	18.9.2004
EU/1/99/112/002/IS	Ziagen, oral liquid, 20 mg/ml	Iceland	16.9.2004
EU/1/99/113/001/NO-004/NO	Paxene	Norway	11.11.2004
EU/1/99/113/001-004	Paxene	Liechtenstein	30.11.2004
EU/1/99/113/001-004/IS	Paxene, concentrate foer solution for infusion, 6 mg/ml	Iceland	23.11.2004
EU/1/99/114/001/NO-003/NO	Zeffix	Norway	18.11.2004
EU/1/99/114/001-002/IS	Zeffix, film-coated tablet, 100 mg	Iceland	19.11.2004
EU/1/99/114/001-003	Zeffix	Liechtenstein	30.11.2004
EU/1/99/114/003/IS	Zeffix, oral solution, 5 mg/ml	Iceland	19.11.2004
EU/1/99/116/001/NO-003/NO	Remicade	Norway	11.10.2004
EU/1/99/116/001-003	Remicade	Liechtenstein	30.9.2004
EU/1/99/117/001/IS	Synagis, powder and solvent fol sol. for injection, 50 mg/hgl	Iceland	7.10.2004
EU/1/99/117/001/NO-002/NO	Synagis	Norway	8.10.2004
EU/1/99/117/001-002	Synagis	Liechtenstein	30.9.2004
EU/1/99/117/002/IS	Synagis, powder and solvent fol sol. for injection, 100 mg/hgl	Iceland	7.10.2004
EU/1/99/118/001/NO-010/NO	Arava	Norway	4.11.2004
EU/1/99/118/001-004/IS	Arava, tablet, 10 mg	Iceland	8.11.2004
EU/1/99/118/001-010	Arava	Liechtenstein	30.11.2004
EU/1/99/118/005-009/IS	Arava, tablet, 20 mg	Iceland	8.11.2004
EU/1/99/118/009/IS	Arava, tablet, 100 mg	Iceland	8.11.2004
EU/1/99/119/001	NovoRapid	Liechtenstein	30.11.2004
EU/1/99/119/001/IS and 008/IS	NovoRapid, solution for injection, 100 units/ml	Iceland	11.11.2004
EU/1/99/119/001/NO EU/1/99/119/003/NO EU/1/99/119/005/NO-014/NO	NovoRapid	Norway	4.11.2004
EU/1/99/119/003	NovoRapid	Liechtenstein	30.11.2004
EU/1/99/119/003/IS and 006/IS	NovoRapid Penfill, solution for injection, 100 units/ml	Iceland	11.11.2004
EU/1/99/119/005/IS and 007/IS	NovoRapid NovoLet, solution for injection, 100 units/ml	Iceland	11.11.2004
EU/1/99/119/005-014	NovoRapid	Liechtenstein	30.11.2004
EU/1/99/119/012-014/IS	NovoRapid InnoLet, solution for injection, 100 units/ml	Iceland	11.11.2004
EU/1/99/125/001/NO-008/NO	Zyprexa Velotab	Norway	4.12.2004
EU/1/99/125/001-004/IS	Zyprexa Velotab, orodispersible tablet	Iceland	1.12.2004
EU/2/98/009/001-006/IS	Suvaxyn Aujezky 738+O/W, emulsion for injection,	Iceland	6.8.2004
EU/2/99/013/001/NO-002/NO	Halocur	Norway	21.12.2004

ANNEX III

3. Extended Marketing Authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July — 31 December 2004:

EU-Number	Product	Country	Date of extention
EU/03/258/007-009/IS	Avandamet 2 mg/1 000 mg, film-coated tablets	Iceland	20.10.2004
EU/03/258/010-012/IS	Avandamet 4 mg/1 000 mg, film-coated tablets	Iceland	20.10.2004
EU/1/00/143/004/IS	KOGENATE Bayer 250 IU Powder and solvent for solution for injection	Iceland	23.10.2004
EU/1/00/143/004/NO-006/NO	Kogenate	Norway	21.10.2004
EU/1/00/143/005/IS	KOGENATE Bayer 500 IU Powder and solvent for solution for injection	Iceland	23.10.2004
EU/1/00/143/006/IS	KOGENATE Bayer 1 000 IU Powder and solvent for solution for injection	Iceland	23.10.2004
EU/1/01/193/002/IS	MabCampath, conc. for sol. for inf. 30 mg/ml	Iceland	26.11.2004
EU/1/02/206/009/NO-017/NO	Arixtra	Norway	8.12.2004
EU/1/02/207/009/NO-017/NO	Quixidar	Norway	8.12.2004
EU/1/03/258/007/NO-012/NO	Avandamet	Norway	24.9.2004
EU/1/97/046/016-030/IS	Aprovel 75, 150 and 300 mg film-coated tablets	Iceland	25.8.2004
EU/1/97/049/016-030/IS	Karvea 75, 150 and 300 mg film-coated tablets	Iceland	25.8.2004
EU/1/98/085/011-020/IS	Karvezide, 150 mg/12,5 mg and 300 mg/12,5 mg film-coated tablets	Iceland	25.8.2004
EU/1/98/086/011-020/IS	CoAprovel 150 mg/12,5 mg and 300 mg/12,5 mg film-coated tablets	Iceland	25.8.2004

ANNEX IV

4. Withdrawn Marketing Authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July — 31 December 2004:

EU-Number	Product	Country	Date of withdrawal
EU/1/01/181/001-007	Ixense	Liechtenstein	30.11.2004
EU/1/01/181/001-007/IS	Ixense	Iceland	8.11.2004
EU/1/01/182/001/NO-010/NO	Taluvian	Norway	10.8.2004
EU/1/01/182/001-010	Taluvian	Liechtenstein	30.9.2004
EU/1/01/182/001-010/IS	Taluvian	Iceland	26.10.2004

28.9.2006

Official Journal of the European Union

C 233/54

List of marketing authorisations granted by the EEA EFTA States for the first half of 2005

(2006/C 233/12)

With reference to EEA Joint Committee Decision No. 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note, at the meeting on 10 March 2006, the following lists concerning marketing authorisations for medicinal products for the period 1 January — 30 June 2005:

Annex I

List of new marketing authorisations

Annex II

List of renewed marketing authorisations

Annex III

List of extended marketing authorisations

Annex IV

List of withdrawn marketing authorisations

ANNEX I

1. New Marketing Authorisations:

The following marketing authorisations have been granted In the EEA EFTA States during the period 1 January — 30 June 2005:

EU-Number	Product	Country	Date of authorisation
EU/1/00/146/028-029	Keppra	Liechtenstein	31.3.2005
EU/1/00/149/001/NO	Panretin	Norway	28.2.2005
EU/1/01/171/011-012	Rapamune	Liechtenstein	31.3.2005
EU/1/01/178/001/IS	Targretin 75 mg, capsule, soft	Iceland	31.1.2005
EU/1/01/183/019	HBVAXPRO	Liechtenstein	31.5.2005
EU/1/01/184/045-056	Nespo	Liechtenstein	31.3.2005
EU/1/01/185/045-056	Aranesp	Liechtenstein	31.3.2005
EU/1/01/198/011-013	Glivec	Liechtenstein	31.1.2005
EU/1/02/227/002	Neulasta	Liechtenstein	31.3.2005
EU/1/02/228/002	Neupopeg	Liechtenstein	31.3.2005
EU/1/02/237/005	Cialis	Liechtenstein	31.1.2005
EU/1/02/239/025-030	Bextra	Liechtenstein	31.1.2005
EU/1/02/246/003	Carbaglu	Liechtenstein	31.5.2005
EU/1/04/285/021-028	Apidra	Liechtenstein	31.5.2005
EU/1/04/296/001/IS	Cymbalta 30 mg, Gastro-resistant capsule, hard	Iceland	14.1.2005
EU/1/04/296/001/NO-004/NO	Cymbalta	Norway	11.1.2005
EU/1/04/296/001-004	Cymbalta	Liechtenstein	31.1.2005
EU/1/04/296/002-005/IS	Cymbalta 60 mg, Gastro-resistant capsule, hard	Iceland	14.1.2005
EU/1/04/297/001/IS	Xeristar 30 mg, Gastro-resistant tablet hard	Iceland	14.1.2005
EU/1/04/297/001/NO-004/NO	Xeristar	Norway	11.1.2005
EU/1/04/297/001-004	Xeristar	Liechtenstein	31.1.2005
EU/1/04/297/002-005/IS	Xeristar 60 mg, Gastro-resistant tablet hard	Iceland	14.1.2005
EU/1/04/298/001/NO-002/NO	Kivexa	Norway	11.1.2005
EU/1/04/298/001-002	Kivexa	Liechtenstein	31.1.2005
EU/1/04/298/001-002/IS	Kivexa 600 mg, film-coated tablet	Iceland	11.1.2005
EU/1/04/299/001/NO-003/NO	Fendrix	Norway	15.2.2005
EU/1/04/299/001-003	Fendrix	Liechtenstein	31.3.2005
EU/1/04/299/001-003/IS	Fendrix 20 microg/0,5 ml, suspension for injection	Iceland	25.2.2005
EU/1/04/300/001/NO-002/NO	Avastin	Norway	18.1.2005
EU/1/04/300/001-002	Avastin	Liechtenstein	31.1.2005
EU/1/04/300/001-002/IS	Avastin 25 mg/ml, concentrate for sol. For infusion	Iceland	11.2.2005
EU/1/04/301/001/NO-005/NO	Quintanrix	Norway	1.3.2005
EU/1/04/301/001-005	Quintanrix	Liechtenstein	31.3.2005
EU/1/04/301/001-005/IS	Quintanrix, powder and solvent for susp. for injection	Iceland	14.3.2005
EU/1/04/302/001/NO-003/NO	Prialt	Norway	17.3.2005
EU/1/04/302/001-003	Prialt	Liechtenstein	31.3.2005
EU/1/04/302/001-003/IS	Prialt, solution for injection	Iceland	18.3.2005
EU/1/04/303/001/IS	Orfadin 2 mg, capsule, hard	Iceland	19.3.2005
EU/1/04/303/003/IS	Orfadin 10 mg, capsule, hard	Iceland	19.3.2005
EU/1/04/303/001/NO-003/NO	Orfadin	Norway	17.3.2005
EU/1/04/303/001-003	Orfadin	Liechtenstein	31.3.2005
EU/1/04/303/002/IS	Orfadin 5 mg, capsule, hard	Iceland	19.3.2005
EU/1/04/304/001/NO-007/NO	Azilect	Norway	21.3.2005
EU/1/04/304/001-007	Azilect	Liechtenstein	31.3.2005
EU/1/04/304/001-007/IS	Azilect 1 mg, tablet	Iceland	17.3.2005
EU/1/04/305/001	Truvada	Liechtenstein	31.3.2005
EU/1/04/305/001/IS	Truvada 245/200 mg, film-coated tablet	Iceland	16.3.2005
EU/1/04/305/001/NO	Truvada	Norway	7.3.2005
EU/1/04/306/001	Aloxi	Liechtenstein	31.5.2005
EU/1/04/306/001/IS	Aloxi 0,25 mg/5 ml, solution for injection	Iceland	7.4.2005
EU/1/04/306/001/NO	Aloxi	Norway	20.4.2005
EU/1/04/307/001/NO-004/NO	Zonegran	Norway	9.4.2005
EU/1/04/307/001-004	Zonegran	Liechtenstein	31.5.2005
EU/1/04/307/003/IS	Zonegran 25 mg, capsule, hard	Iceland	6.4.2005
EU/1/04/307/003/IS	Zonegran 50 mg, capsule, hard	Iceland	6.4.2005
EU/1/05/308/001	Aclasta	Liechtenstein	31.5.2005
EU/1/05/308/001/IS	Aclasta 5 mg/ml, solution for infusion	Iceland	9.5.2005
EU/1/05/308/001/NO	Aclasta	Norway	10.5.2005
EU/1/97/044/001-006/IS	Tasmar	Iceland	18.1.2005
EU/1/97/045/004	Helicobacter Test INFAI	Liechtenstein	31.3.2005
EU/1/99/107/004	Rebetol	Liechtenstein	31.3.2005
EU/1/99/120/001/NO-004/NO	Ammonaps	Norway	21.4.2005
EU/1/99/123/011	Renagel	Liechtenstein	31.3.2005
EU/1/99/125/005-008	Zyprexa Velotab	Liechtenstein	31.3.2005
EU/1/99/126/004-005	Enbrel	Liechtenstein	31.3.2005
EU/1/99/126/006-011	Enbrel	Liechtenstein	31.5.2005
EU/2/00/019/005-007	Eurifel FeLV	Liechtenstein	31.5.2005
EU/2/03/037/001-004/IS	ProteqFlu, powder and solvent for susp. for inj.	Iceland	9.5.2005
EU/2/03/038/001-004/IS	ProteqFlu-Te, powder and solvent for susp. for inj.	Iceland	18.2.2005
EU/2/04/046/001-003/IS	Nobivac Piro, suspension for injection	Iceland	12.5.2005
EU/2/04/047/001/NO-002/NO	Purevax RCPCh FeLV	Norway	21.3.2005
EU/2/04/047/001-002	Purevax RCPCh FeLV	Liechtenstein	31.3.2005
EU/2/04/047/001-002/IS	Purevax RCPCh Fel V	Iceland	30.6.2005
EU/2/04/048/001/NO-002/NO	Purevax RCP FeLV	Norway	21.3.2005
EU/2/04/048/001-002	Purevax RCP FeLV	Liechtenstein	31.3.2005
EU/2/04/048/001-002/IS	Purevax RCP FeL V	Iceland	30.6.2005
EU/2/04/049/001/NO-002/NO	Purevax RCCh	Norway	21.3.2005
EU/2/04/049/001-002	Purevax RCCh	Liechtenstein	31.3.2005
EU/2/04/050/001/NO-002/NO	Purevax RCPCh	Norway	21.3.2005
EU/2/04/050/001-002	Purevax RCPCh	Liechtenstein	31.3.2005
EU/2/04/051/001/NO-002/NO	Purevax RC	Norway	21.3.2005
EU/2/04/051/001-002	Purevax RC	Liechtenstein	31.3.2005
EU/2/04/051/001-002/IS	Purevax RC, powder and solvent for susp. for inj.	Iceland	30.6.2005
EU/2/04/052/001/NO-002/NO	Purevax RCP	Norway	21.3.2005
EU/2/04/052/001-002	Purevax RCP	Liechtenstein	31.3.2005
EU/2/04/052/001-002/IS	Purevax RCP, powder and solvent for susp. for injection	Iceland	30.6.2005
EU/2/04/49/001-002/IS	Purevax RCCh, powder and solvent for susp. for inj.	Iceland	30.6.2005
EU/2/04/50/001-002/IS	Purevax RCPCh, powder and solvent for susp. for inj.	Iceland	30.6.2005
EU/2/05/053/001/IS	Naxel 100 mg/ml, suspension for injection	Iceland	9.6.2005
EU/2/05/053/001/NO	Naxcel	Norway	17.6.2005
EU/2/99/014/012	Stronghold	Liechtenstein	31.1.2005
EU/2/99/015/001/NO	Oxyglobin	Norway	5.1.2005
EU/2/99/017/001-006/IS	Ibraxion, emulsion for injection	Iceland	10.5.2005

ANNEX II

2. Renewed Marketing Authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January — 30 June 2005:

EU-Number	Product	Country	Date of renewal
EU/1/00/129/001/NO-003/NO	Azopt	Norway	30.6.2005
EU/1/00/129/001-003/IS	Azopt, eye drops, suspension, 1%	Iceland	30.6.2005
EU/1/00/130/001/NO-002/NO	Orgalutran	Norway	4.4.2005
EU/1/00/130/001-002	Orgalutran	Liechtenstein	31.3.2005
EU/1/00/130/001-002/IS	Orgalutran	Iceland	18.4.2005
EU/1/00/131/001/NO-050/NO	PegIntron	Norway	24.6.2005
EU/1/00/131/001-050/IS	PegIntron	Iceland	28.6.2005
EU/1/00/132/001/NO-050/NO	ViraferonPeg	Norway	24.6.2005
EU/1/00/132/001-050/IS	ViraferonPeg	Iceland	28.6.2005
EU/1/99/100/001/NO-003/NO	Cetrotide	Norway	4.1.2005
EU/1/99/120/001-002/IS	Ammonaps, tablets, 500 mg	Iceland	29.4.2005
EU/1/99/120/003-004/IS	Ammonaps 940 mg/g, granules	Iceland	29.4.2005
EU/1/99/122/001/NO-002/NO	Thyrogen	Norway	15.4.2005
EU/1/99/122/001-002/IS	Thyrogen, powder for solution for injection, 0,9 mg	Iceland	14.4.2005
EU/1/99/123/001/NO-011/NO	Renagel	Norway	4.2.2005
EU/1/99/123/001-004/IS	Renagel, capsule, hard, 403 mg	Iceland	25.2.2005
EU/1/99/123/001-010	Renagel	Liechtenstein	31.3.2005
EU/1/99/123/005-007/IS	Renagel, film-coated tablet, 400 mg	Iceland	25.2.2005
EU/1/99/123/008-011/IS	Renagel, film-coated tablet, 800 mg	Iceland	25.2.2005
EU/1/99/124/001/IS	Tractocile, solution for injection, 7,5 mg/ml	Iceland	1.3.2005
EU/1/99/124/001/NO-002/NO	Tractocile	Norway	7.3.2005
EU/1/99/124/001-002	Tractocile	Liechtenstein	31.3.2005
EU/1/99/124/002/IS	Tractocile, concentrate for solution for infusion, 7,5 mg/ml	Iceland	1.3.2005
EU/1/99/125/001-004	Zyprexa Velotab	Liechtenstein	31.3.2005
EU/1/99/126/001/NO-005/NO	Enbrel	Norway	6.4.2005
EU/1/99/126/001-003	Enbrel	Liechtenstein	31.3.2005
EU/1/99/126/001-005/IS	Enbrel	Iceland	15.4.2005
EU/1/99/127/001/NO-044/NO	IntronA	Norway	20.6.2005
EU/1/99/127/001-044/IS	IntronA	Iceland	27.6.2005
EU/1/99/128/001/NO-037/NO	Viraferon	Norway	20.6.2005
EU/1/99/128/001-037/IS	Viraferon	Iceland	27.6.2005
EU/2/00/018/001/IS	Incurin, tablet, 1mg	Iceland	10.5.2005
EU/2/00/018/001/NO	Incurin	Norway	16.6.2005
EU/2/00/019/001/NO-003/NO	Eurifel FeLV	Norway	31.5.2005
EU/2/00/019/001-003	Eurifel FeLV	Liechtenstein	31.5.2005
EU/2/00/021/001/NO-002/NO	Rabigen	Norway	23.5.2005
EU/2/00/021/001-002/IS	RABIGEN SAG2, oral suspension	Iceland	9.5.2005
EU/2/99/013/001-002	Halocur	Liechtenstein	31.1.2005
EU/2/99/013/001-002/IS	Halocur 0.5 mg/ml, oral solution	Iceland	18.2.2005
EU/2/99/014/001/NO-012/NO	Stronghold	Norway	6.1.2005
EU/2/99/014/001-011	Stronghold	Liechtenstein	31.1.2005
EU/2/99/014/001-012/IS	Stronghold spot on solution 6% and 12%	Iceland	7.1.2005
EU/2/99/015/001	Oxyglobin	Liechtenstein	31.1.2005
EU/2/99/015/001/IS	Oxyglobin 13g/dl, solution for infusion	Iceland	5.1.2005
EU/2/99/017/001/NO-006/NO	Ibraxion	Norway	2.6.2005
EU/2/99/017/001-006	Ibraxion	Liechtenstein	31.5.2005

ANNEX IV

4. Withdrawn Marketing Authorisations

The following marketing authorisations have been withdrawn in EEA EFTA States during the period 1 January — 31 June 2005:

EU-Number	Product	Country	Date of extention
EU/1/01/171/011/NO-012/NO	Rapamune	Norway	2.2.2005
EU/1/01/171/011-012/IS	Rapamune 5 mg filmcoated tablets	Iceland	1.3.2005
EU/1/02/206/009-011/IS	Arixtra 5mg/0,4 ml solution for injection	Iceland	10.3.2005
EU/1/02/206/012-014/IS	Arixtra 7,5mg/0,6 ml solution for injection	Iceland	10.3.2005
EU/1/02/206/015-017/IS	Arixtra 10mg/0,8 ml solution for injection	Iceland	10.3.2005
EU/1/02/207/009-011/IS	Quixidar 5mg/0,4 ml solution for injection	Iceland	9.3.2005
EU/1/02/207/012-014/IS	Quixidar 7,5mg/0,6 ml solution for injection	Iceland	9.3.2005
EU/1/02/207/015-017/IS	Quixidar 10mg/0,8 ml solution for injection	Iceland	9.3.2005
EU/1/96/026/002/NO	Invirase	Norway	9.6.2005
EU/1/99/107/004/IS	Rebetol, oral solution 40 mg/ml	Iceland	22.3.2005
EU/1/99/107/004/NO	Rebetol	Norway	22.2.2005
EU/1/99/126/006/NO-011/NO	Enbrel	Norway	19.5.2005
EU/1/99/126/006-011/IS	Enbrel, 50 mg	Iceland	24.5.2005
EU/2/00/019/005/NO-007/NO	Eurifel FeLV	Norway	15.4.2005

ANNEX IV

4. Withdrawn Marketing Authorisations

The following marketing authorisations have been withdrawn in EEA EFTA States during the period 1 January — 31 June 2005:

EU-Number	Product	Country	Date of withdrawal
EU/1/00/138/001/NO-012/NO	Venvia	Norway	4.1.2005
EU/1/00/138/001-012	Venvia	Liechtenstein	31.1.2005
EU/1/00/139/001/NO-012/NO	Nyracta	Norway	4.1.2005
EU/1/00/139/001-012	Nyracta	Liechtenstein	31.1.2005
EU/1/01/181/001/NO-007/NO	Ixense	Norway	6.1.2005
EU/1/97/048/001/NO-014/NO	Infanrix HepB	Norway	25.5.2005
EU/1/97/048/001-014	Infanrix HepB	Liechtenstein	31.5.2005
EU/1/97/048/001-014/IS	Infanrix HepB	Iceland	15.6.2005

		ISSN 1725-2423
Official Journal of the European Union		C 233

English edition	Information and Notices	Volume 49 28 September 2006

Notice No	Contents	page
	I Information
	Commission
2006/C 233/1	Euro exchange rates	1

2006/C 233/2	Prior notification of a concentration (Case COMP/M.4242 — Thermo Electron Corporation/Fisher Scientific International) ( 1 )	2

2006/C 233/3	Prior notification of a concentration (Case COMP/M.4379 — Remondis/Cronimet/Alfa Acciai/TSR Group) — Candidate case for simplified procedure ( 1 )	3

2006/C 233/4	Prior notification of a concentration (Case COMP/M.4390 — PHL/IBFF) — Candidate case for simplified procedure ( 1 )	4

2006/C 233/5	State aid — Italy — State aid No C 31/2006 (ex N 612/2005) — Urgent measures to prevent bird flu — Invitation to submit comments pursuant to Article 88(2) of the EC Treaty	5

2006/C 233/6	Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 68/2001 of 12 January 2001 on the application of Articles 87 and 88 of the EC Treaty to training aid ( 1 )	9

2006/C 233/7	Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 68/2001 of 12 January 2001 on the application of Articles 87 and 88 of the EC Treaty to training aid ( 1 )	17

	EUROPEAN ECONOMIC AREA
	Standing Committee of the EFTA States
2006/C 233/8	List of marketing authorisations granted by the EEA EFTA States for the first half of 2003	21

2006/C 233/9	List of marketing authorisations granted by the EEA EFTA States for the second half of 2003	28

2006/C 233/0	List of marketing authorisations granted by the EEA EFTA States for the first half of 2004	37

2006/C 233/1	List of marketing authorisations granted by the EEA EFTA States for the second half of 2004	45

2006/C 233/2	List of marketing authorisations granted by the EEA EFTA States for the first half of 2005	54

	III Notices
	Commission
2006/C 233/3	Notice of invitation to tender for the reduction in the import duty on maize imported from non-member countries	61

	Currency	Exchange rate
USD	US dollar	1,2684
JPY	Japanese yen	148,90
DKK	Danish krone	7,4595
GBP	Pound sterling	0,67105
SEK	Swedish krona	9,2770
CHF	Swiss franc	1,5796
ISK	Iceland króna	88,77
NOK	Norwegian krone	8,2650
BGN	Bulgarian lev	1,9558
CYP	Cyprus pound	0,5767
CZK	Czech koruna	28,413
EEK	Estonian kroon	15,6466
HUF	Hungarian forint	273,63
LTL	Lithuanian litas	3,4528
LVL	Latvian lats	0,6960
MTL	Maltese lira	0,4293
PLN	Polish zloty	3,9782
RON	Romanian leu	3,5350
SIT	Slovenian tolar	239,59
SKK	Slovak koruna	37,443
TRY	Turkish lira	1,8965
AUD	Australian dollar	1,6915
CAD	Canadian dollar	1,4143
HKD	Hong Kong dollar	9,8784
NZD	New Zealand dollar	1,9264
SGD	Singapore dollar	2,0156
KRW	South Korean won	1 196,86
ZAR	South African rand	9,6795
CNY	Chinese yuan renminbi	10,0229
HRK	Croatian kuna	7,3945
IDR	Indonesian rupiah	11 681,96
MYR	Malaysian ringgit	4,670
PHP	Philippine peso	63,693
RUB	Russian rouble	33,9790
THB	Thai baht	47,603